

REFERENCES

REFERENCES

- Acharya, K., Samui, K., Rai, M., Dutta B. B. and Acharya, R. (2004). Antioxidant and nitric oxide synthase activation properties of *Auricularia auricula*. **Indian Journal of Experimental Biology**, **42**: 538-540.
- Agarwal K. C., Russo, F. X. and Parks, R. E. Jr. (1982). Inhibition of human and rats platelet aggregation by extracts of Moer (*Auricularia auricula*). **Thrombosis and Haemostasis**, **48(2)**: 162-165.
- Ajith, T. A., and Janardhanan, K. K. (2001). Antioxidant and anti-inflammatory activities of methanolic extract of *Phellinus rimosus* (Berk) pilat. **Indian Journal of Experimental Biology**, **39**: 1166-1169.
- Ali, N. A. A., Pilgrim, H., Liberra, K., Lindequist, U. and Jansen, R. (1996b). Hispolon, a yellow pigment from *Inonotus hispidus*. **Phytochemistry**, **41**: 927-929.
- Amarowicz, R., Pegg, R. B., Rahimi-Moghaddam, P., Barl, B., & Weil, J.A. (2004). Free-radical scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies. **Food Chemistry**, **84**:551–562.
- Ames, B. N., Shigenaga, M. K., and Hagen, T. M. (1993). Oxidants, antioxidants, and the degenerative diseases of aging. **Proceedings of the National Academy of Sciences of the United States of America**, **90**: 7915-7922.
- Ames, B. N., Shigenaga, M. K. and Hagen, T. M. (1995). Mitochondrial decay in aging. **Biochimica et Biophysica Acta**, **1271**: 165–170.
- Aprikian, O., Levrat-Verny, M., Besson, C., Busserolles, J., Remesy, C. and Demigne, C. (2001). Apple favourably affects parameters of cholesterol metabolism and of anti-oxidative protection in cholesterol fed rats. **Food Chemistry**, **75**:445-452.
- Argano, M., Brignardello, E., Tamagno, O. and Boccuzzi, G. (1997). Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats. **Journal of Endocrinology**, **155**: 233-240
- Arnao, M.B. (2000). Some methodological problems in the determination of antioxidant activity using chromogen radicals: a practical case. **Trend in Food Sciences & Technology**, **11**: 419-421.
- Arner, P., Pollace, T., and Lithell, H. (1991). Different etiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non-obese subjects. **Diabetologia**, **34**:483-487.
- Badole, S. L., Shah, S. N., Patel, N. N., Thakurdesai, P. A., Bodhankar, S. L. (2006a). Hypoglycemic activity of aqueous extract of *Pleurotus pulmonarius* (Fr.) Quel.-Champ in alloxan induced diabetic mice. **Pharmaceutical Biology**, **44** :421-425.
- Bailey, C. J., and Puah, J. A. (1986). Effect of metformin on glucose metabolism in mouse soleus muscle. **Diabète et Metabolisme**, **12**: 212-218.

Bano, Z. The nutritive value of mushrooms. (1976). **First Symposium on Survey and Cultivation of Edible Mushrooms of India**. (pp. 148-169). Regional Research Laboratory, Jammu.

Barja, G. and Herrero, A. (2000). Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. **FASEB Journal**, **14(2)** :312–318.

Barrett, E. J., DeFranzo, R. A., Bevilacqua, S. and Ferrannini, E. (1982). Insulin resistance in diabetic ketoacidosis. **Diabetes**, **31(10)** :923-928.

Barros, L., Ferreira, M. J., Queiros, B., Ferreira, I. C. F. R. and Baptista, P. (2007). Total phenols, ascorbic acid, β -carotene and lycopene in Portuguese wild edible mushrooms and their antioxidant activities. **Food Chemistry**, **103**: 413-419.

Beers, R. F., Jr., and Sizer, I. W. (1952). A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. **Journal of Biological Chemistry**, **195** :133-140.

Benzie, I. F. F., and Strain, J. J. (1996). Ferric reducing ability of plasma (FRAP) as measure of total antioxidant power. **Journal of Analytical Biochemistry**, **239** :70-76.

Benzie, I. F. F., Szeto, Y. T. (1999). Total antioxidant capacity of teas by the ferric reducing/antioxidant power (FRAP) assay. **Journal of Agricultural Food Chemistry**, **47**: 633-637.

Bianco, C. (1981). Basidiomycetes in relation to antibiosis. II. Antibiotic activity of mycelia and culture liquids. **Giornale di Batteriologia, Virologia ed Immunologia**, **74(7-12)** :267-274.

Bjorntop, P. (1988). Abdominal obesity and the development of non-insulin dependent diabetes mellitus. **Diabetes Metabolism Review**, **4** :615-622.

Bobek, P., Ozdin, L. and Kunial, L. (1995). Antioxidative effect of oyster mushroom (*Pleurotus ostreatus*) in hypocholesterolemic rat. **Pharmazie**, **50** :441–442.

Bobek, P. and Galbavy, S. (2001). Effect of pleuran (beta-glucan from *Pleurotus ostreatus*) on the antioxidant status of the organism and on dimethylhydrazine-induced precancerous lesions in rat colon. **British Journal of Biomedical Science**, **58**:164–168.

Bohn, J.A. and BeMiller, J.N. (1995). (1-3)- β -glucans as biological response modifiers: a review of structure--functional activity relationships. **Carbohydrate Polymerase**, **28** :3-14.

Boyd A. E. (1988). Sulfonylurea receptors, ion channels, and fruit flies. **Diabetes**, **37** :847-850.

Brand-Williams, W., Cuvelier, M. E. and Berset, C. (1995). Use of a free radical method to evaluate antioxidant activity. **LWT Food Science and Technology**, **28** :25-30.

- Bravo, L. (1998). Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. **Nutritional Review**, **56** :317-333.
- Breene, W. M. (1990). Nutritional and medicinal value of speciality mushrooms. **Journal of Food Protection**, **53** :883-894.
- Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. **Nature**, **414** :813-820.
- Butkovic, V. (2004). Kinetic Study of Flavonoid Reactions with Stable Radicals. **Journal of Agriculture and Food Chemistry**, **52** :2816-2820.
- Calhoun, W. J., Reed, H. E., Moest, D. R., and Stevens, C. A. (1992). Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. **American Review Respiratory Disease**, **145** :317-325.
- Cantin, P. A. (1999). Oxidant and antioxidants in lung injury. in **Lam and Other Diseases Characterized by Smooth Muscle Proliferation**. ed. Moss, J. (Dekker, New York), pp 519-531.
- Cao, G., Alessio, H. M., and Cutler, R. G. (1993). Oxygen-radical absorbance capacity assay for antioxidants. **Free Radical Biology and Medicine**, **14** :303-311.
- Cao, G., Russell, R. M., Lischner, N. and Prior, R. L. (1998). Serum antioxidant capacity is increased by consumption of strawberries, spinach, red wine or vitamin C in elderly women. **Journal of Nutrition**, **128** :2383-2390.
- Carey, D., Jenkins, A., Campbell, L., Freund, J., and Chisholm, D. (1996). Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. **Diabetes**, **45** :633-638.
- Ceriello, A., Bortolotti, N., Motz, E., Crescentini, A., Lizzio, S., Russo, A., Tonutti, L. and Taboga, C. (1998). Meal-generated oxidative stress in type 2 diabetic patients. **Diabetes Care**, **21** :1529-1533.
- Chang, R. (1996). Functional properties of edible mushrooms. **Nutrition Review**, **54** :91-93.
- Chang, S. T. (1993). Mushroom biology: the impact on mushroom production and mushroom products. In: S. T. Chang *et al.* (eds.). **Mushroom biology and mushroom products**. The Chinese University of Hong Kong.
- Chang, S. T., and J. A. Buswell. (1999). *Ganoderma lucidum* (Curt.:Fr.) P. Karst. (Aphyllphoromycetidae) – A Mushrooming Medicinal Mushroom. **International Journal of Medicinal Mushrooms**, **1** :139-146.
- Chang, S. T. 1999. World production of cultivated edible and medicinal mushrooms in 1997 with emphasis on *Lentinus edodes* (Berk.) Sing. in China. **International Journal of Medicinal Mushrooms**, **1** :291-300.

Charles, M. A., Eschwege, E. and Thibault, N. *et al.* (1997). The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. **Diabetologia**, **40** :1101-1106.

Charles, M. and Clark, Jr. (1998). How Should We Respond to the Worldwide Diabetes Epidemic? **Diabetes Care**, **21** :475-476.

Cheung, L. M., Cheung, P. C. K. and Ooi, V. E. C. (2003). Antioxidant activity and total phenolics of edible mushroom extracts. **Food Chemistry**, **81** :249-255.

Cheung, L. M. and Peter, P. C. K. (2005). Mushroom extracts with antioxidant activity against lipid peroxidation. **Food Chemistry**, **89** :403-409

Cheung, P. C. K. (1997). Dietary fiber content and composition of some edible fungi determined by two methods of analysis. **Journal of Science, Food and Agriculture**, **73** :255–260.

Chopra, R. N., Chopra, I. C., Handa, K. L. and Kapur, L. D. (1958). Medicinal plants in diabetes. In: Gupta P, editor. **Indigenous Drugs of India**. 2nd ed. Calcutta, India: Dhur and Sons. pp. 314–319.

Cohen, R., Persky, L. and Hadar, Y. (2002). Biotechnological applications and potential of wood-degrading mushrooms of the genus *Pleurotus*. **Applied Microbiology and Biotechnology**, **58** :582-594.

Cullen, W. J., Dulchavsky, S. A., Devasagayam, T. P. A., Venkataraman, B. V., and Dutta, S. (1997). Effect of Maharishi-4 on H₂O₂-induced oxidative stress in isolated rat hearts. **Journal of Ethnopharmacology**, **56** :215-222.

DeFronzo, R. A., Binder, C., Wahren, J., Felig, P., Ferrannini, E., and Faber, O. (1981). Sensitivity of insulin secretion to feedback inhibition by hyperinsulinemia. **Acta Endocrinologica (Copenhagen)**, **98** :81-84.

Del Prato, S., Leonetti, F., Simonson, D. C., Sheehan, P., Matsuda, M., and DeFronzo, R. A. (1994). Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man. **Diabetologia**, **37** :1025-1035.

Dennog, C., Radermacher, P., Barnett, Y. A. and Speit, G. (1999). Antioxidant status in humans after exposure to hyperbaric oxygen. **Mutation Research**, **16** :83-89.

Devasagayam, T. P. A., Bloor, K. K. and Ramasarma, T. (2003). Methods for estimating lipidperoxidation. An analysis merits and demerits (mini review). **Journal of Biochemistry and Biophysics**, **40** :300-308.

Devasagayam, T. P. A., Kamat, J. P. and Sreejayan, N. (2001). Antioxidant action of curcumin. In: **Micronutrients and Health: Molecular Biological Mechanisms**. (eds. Nesaretnam, K. and Packer, L.). AOCS Press, Champaign, IL, USA. pp. 42–59.

Dobree, J. H. (1970). Simple diabetic retinopathy. Evolution of lesions and therapeutic considerations.: **British Journal of Ophthalmology**, **54** 1–10.

- Duthie, S. J., Ma, A., Ross, M. A. and Collins, A. R. (1996). Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. **Cancer Research**, **56** :1291–1295.
- Eisenhur, R., and Fritz, D. (1991). Medicinally effective and health promoting compounds of edible mushrooms. **Gartenbrauwissenschaft**, **56** :266-270.
- Ekanem, E. O. and Ubengama, V. S. (2002). Chemical composition, anti-nutritional factors and shelf life of Oyster mushroom (*Pleurotus ostreatus*). **Journal of Food, Science and Technology**, **39** :635-638.
- Elmi, A., Idahl, L. A., and Sehlin, J. (2000). Relationships between the Na(+)/ K(+) pump and ATP and ADP content in mouse pancreatic islets: Effects of meglitinide and glibenclamide. **British Journal of Pharmacology**, **131** :1700-1706.
- El-Missiry, M. A., Othman, A. I. and Amer M. A. (2004). L-Arginine ameliorates oxidative stress in alloxan-induced experimental diabetes mellitus. **Journal of Applied Toxicology**, **24(2)** :93–97.
- Erdogan, H., Fadillioglu, E., Yagmurca, M., Ucar, M. and Irmak, M. K. (2006). Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury: Protective effects of erdosteine and N-acetylcysteine. **Urological Research**, **34** :41-46.
- Ewart, R. B., Kornfeld, S., and Kipnis, D. M. (1975). Effect of lectins on hormone release from isolated rat islets of langerhans. **Diabetes**, **24** :705-714.
- Fagan, T. C., and Deedwania, P. C. (1998). The cardiovascular dysmetabolic syndrome. **American Journal of Medicine**, **105** :775-825.
- Fang, Y. Z. Yang, S., and Wu, G. Y. (2002). Free radicals, antioxidants and nutrition. **Nutrition**, **18** :872-879.
- Feher, J., Casmos, G. and Verekei, A. (1987). **Free Radical Reactions in Medicine**. Springer Verlag, Berlin, Heidelberg, pp: 1-42.
- Ferrannini, E., and Stern, M. P. (1995). Primary insulin resistance: a risk syndrome. In: Leslie, R. D. G., and Robbins, D. C. (Eds.). **Diabetes: Clinical Science In Practice**. (pp. 200-220). Cambridge University Press, Cambridge.
- Ferreira, I. C. F. R., Baptista, P., Vilas-Boas, M. and Barros, L. (2007). Free-radical scavenging capacity and reducing power of wild edible mushrooms from northeast Portugal: Individual cap and stipe activity. **Food Chemistry**, **100** :1511-1516.
- Fink, R. I., Wallace, P., Brechtel, G. and Olefsky, J. M. (1992). Evidence that glucose transport is rate-limiting for in-vivo glucose uptake. **Metabolism**, **41** :897-902.
- Flegg, P. B., and Maw, G. A. (1976). Mushroom and their possible contribution to world protein needs. **Mushrooms Journal**, **48** :396-405.
- Fraga, C. G., Motchnik, P. A., Shigenaga, M. K., Helbock, H. J., Jacob, R. A. and Ames, B. N. (1991). Ascorbic acid protects against endogenous oxidative DNA damage

in human sperm. **Proceedings of the National Academy of Sciences of the United States of America**, **88** :11003–6.

Fukae, J., Takanashi, M., Kubo S. *et al.* (2005). Expression of 8 – oxoguanine DNA glycosylase (OGG 1) in Parkinson’s disease and related neurodegenerative disorders. **Acta Neuropathologica (Bert)**, **109** :256-262.

Garg, M. C., Ojha, S., and Bansal, D. D. (1996). Antioxidant status of streptozotocin diabetic rats. **Indian Journal of Experimental Biology**, **34** :264-266.

Garzillo, A.M.V., S. Di Paolo, M. Ruzzi and V. Buonocore, (1994). Hydrolytic properties of extracellular cellulases from *Pleurotus ostreatus*. **Applied Environmental Microbiology**, **42** :476-481.

Gepts, W. and Lecompte, M. (1981). The pancreatic islets in diabetes. **American Journal of Medicine**, **70** :105-115.

Gorray, K. C., Sorresso, D., Moak, S. A., Maimon, J., Greenwald, R. A., and Schneider, B. S. (1993). Comparison of superoxide dismutase activities in isolated rat and guinea pig islets of Langerhans. **Hormone and Metabolic Research**, **25(12)** :649–650.

Grankvist, K., Marklund, S., and Taljedal, I. B. (1981). Superoxidase dismutase is prophylactic against alloxan diabetes. **Nature**, **294** :158-161.

Gray, A. M., and Flatt P. R. (1997). Nature’s own pharmacy: the diabetes perspective. **Proceedings Nutritional Society**, **6** :507-517.

Gray, A. M., and Flatt P. R. (1998). Insulin-releasing and insulin-like activity of *Agaricus campestris* (mushroom). **Journal of Endocrinology**, **157** :259-266.

Gregori, A. (2007). Cultivation of *Pleurotus* spp. **Food Technology in Biotechnology**, **45 (3)** :236–247.

Groop, L. C. (1992). Sulfonylureas in NIDDM. **Diabetes Care**, **15** :737-754.

Gunde-Cimerman N. and Cimerman A. (1995). *Pleurotus* fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. **Experimental Mycology**, **19 (1)** :1–6.

Gunde-Cimerman N. (1999). Medicinal value of the genus *Pleurotus* (Fr.) P. Karst. (*Agaricales* s. l. , Basidiomycetes). **International Journal of Medicinal Mushrooms**, **1** :69-80.

Guo, C. J., and Yang, J. J. (2001). Progress in the study of antioxidant capacity of fruits and vegetables. **China Public Health**, **17** :87-88.

Hadar, Y. and Cohen-Arazi, E. (1986). Chemical composition of the edible mushroom *Pleurotus ostreatus* produced by fermentation. **Applied Environmental Microbiology**, **51** :1352–1354.

Ha, H. and Lee, H. B. (2000). Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. **Kidney International Supplement**, **77** :S19-25.

Halliwell, B. (1990). How to characterize a biological antioxidant. **Free Radical Research Communication**, **9 (1)** :1-32.

Halliwell, B. and Gutteridge, J. M. (1990). Role of free radicals and catalytic metal ions in human disease: an overview. **Methods in Enzymology**, **186** :1–85.

Halter, J. B., Beard J. C. and Porte D. Jr. (1984). Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. **Endocrinology and Metabolism**, **247** :E47-E52.

Halvorsen, B. L., Holte, K., Myhrstad, M. C. W., Barikmo, I., Hvattum, E., Remberg, S. F., Wold, A. B., Haffner, K., Baugerød, H., Andersen, L. F., Moskaug, J. Ø., Jacobs, Jr. D. R., and Blomhoff, R. (2002). A systematic screening of total antioxidants in dietary plants. **Journal of Nutrition**, **132** :461-471.

Hardy, K. L., and Mc Nutty, S. J., (1997). Oral hypoglycaemic agents. **Medicine Digest**, **23** :5-9.

Hatano, T., Edamatsu, R., Hiramatsu, M., Moti, A., Fujita, Y., Yasuhara, T., Yoshida, T., and Okuda, T. (1989). Effects of tannins and related polyphenols on superoxide anion radical, and on 1,1-diphenyl-2-picrylhydrazyl radical. **Chemical and Pharmaceutical Bulletin**, **37** :2016-2021.

Heled, Y., Shapiro, Y., Shani, Y., Moran, D. S., Langzam, L., Braiman, L., Sampson, S. R., and Meyerovitch, J. (2003). Physical exercise enhances protein kinase C delta activity and insulin receptor tyrosine phosphorylation in diabetes-prone psammomys obesus. **Metabolic and Clinical Experiments**, **52** :1028-1033.

Heptinstall, R. H. (1983). Chronic glomerulonephritis, end-stage kidney and visceral changes in chronic renal failure. In: **Pathology of the Kidney** (3rd ed), edited by Heptinstall RH, Boston, Little, Brown and Co. pp:601-36.

Hidaka, H. and Ikegawa, T. (1998). Anticancer agents from edible mushrooms. Japan Patent JP 48006766, B4 730228 Showa.

Hilber, O. (1997). The genus *Pleurotus* (Fr.) Kummer. **Erschienen im Selbstverlag**.

Hobbs, C. (1995). Medicinal mushrooms: an exploration of tradition, healing and culture. **Botanica Press**, Santa Cruz, California.

Hsu, F. L., Lai, C. W., Cheng, J. T. (1997). Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of *Paeonia lactiflora*. **Planta Medica**, **63** :323-325.

Hua, L., Zhang, L., Dong, L., and Cao, J. (1994). Preparation and immunologic competence of glycopeptide components from *Pleurotus ostreatus* fungi. **Shangdong Yike Daxue Xuebao**, **32** :343-346.

- Hu, S. H., Wang, J. C., Lien, J. L., Liaw, E. T., and Lee, M. Y. (2006). Antihyperglycemic effect of polysaccharide from fermented broth of *Pleurotus citrinopileatus*. **Applied Microbiology and Biotechnology**, **70** :107-113.
- Imlay, J. A. (2003). Pathways of oxidative damage. **Annual Review of Microbiology**, **57** :395-418.
- Irinoda, K., Mashihhi, N. K., Chihara, G., Kaneko, Y., and Katori, T (1992). Stimulation of microbicidal host defence mechanism against aerosol influenza virus infection by *Lentinan*. **International Journal of Immunopharmacology**, **14 (6)** :971-977.
- Jacob, R. A. (1995). The integrated antioxidant system. **Nutrition Research**, **15** :755-766.
- Jose N., and Janardhanan K. K. (2000). Antioxidant and antitumor activity of *Pleurotus florida*. **Current Science**, **79** :941-943.
- Jose, N. Ajith, T. A., and Jananrdhanan, K. K. (2002). Antioxidant, anti-inflammatory and antitumor activities of culinary-medicinal mushroom *Pleurotus pulmonarius* (Fr.) Quel. (Agaricomycetidae). **International Journal of Medicinal Mushrooms**, **4** :329-335.
- Jukka, M., Paul, K., Ritva, J., and Antti, R. (2004). Dietary antioxidant intake and risk of type 2 diabetes. **Diabetes Care**, **27(2)** :362-366.
- Jung, G. T., Ju, I. O., Yu, Y. Z., Ryu, J., Choi, J. S. and Choi, Y. G. (2003). Mycelial yield of *Pleurotus ostreatus* using trimmed apple, pear and peach on submerged culture. **Biotechnology and Bioprocess Engineering**, **8** :286-290.
- Kagansky, N., Levy, S., Rimon, E., Cojocar, L., Fridman, A., Ozer, Z., and Knobler H. (2003). Hypoglycemia as a predictor of mortality in hospitalized elderly patients. **Archives of International Medicine**, **163** :1825-1829.
- Kamat, J. P., Bloor, K. K., Devasagayam, T. P. and Venkatachalam, S. R. (2000). Antioxidant properties of *Asparagus racemosus* against damage induced by gamma-radiation in rat liver mitochondria. **Journal of Ethnopharmacology**, **71** :425-35.
- Kamath, V. G., Chandrashekar, A., and Rajini, P. S. (2004). Antiradical properties of sorghum (*Sorghum bicolor* L. Moench) flour extracts. **Journal of Cereal Science**, **40** :283-288.
- Kar, S., Wang, Z., Wang, M., Adachi, T., Wilcox, C. S., Lazo, J. S. and Carr, B. I. (2001). PTP antagonizing K vitamin analogs: A new class of growth inhibitor. **Signal Transduction**, **1** :166.
- Kaur, C., and Kapoor, H. C. (2001). Review: Antioxidants in fruits and vegetables – the millennium's health. **International Journal of Food Science and Technology**, **36** :703-725.

Kawamura, M., Heinecke, J. W. and Chait, A. (1994). Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. **Journal of Clinical Investigation**, **94**(2) :771–778.

Khanna, P., and Garcha, H. S. (1984). *Pleurotus* mushroom- A source of food protein. **Mushroom News Letter Tropics**, **4** :9-14.

Kho Y.S, Vikineswary S, Abdullah N, Kuppusamy U.R, Oh H.I. (2009) Antioxidant capacity of fresh and processed fruit bodies and mycelium of *Auricularia auricula-judae* (Fr.) Quél. **Journal of Medicinal Food**, **12**(1) :167-74.

Kiho, T., Marimoto, H., Kobayashi, T., Usui, S., Ukai, S., Aiwaza, K., Inakuma, T. (2000). Effect of a Polysaccharide (TAP) from the Fruiting Bodies of *Tremella aurantia* on Glucose Metabolism in Mouse Liver. **Bioscience, Biotechnology and Biochemistry**, **64** :417-419.

Kim, S. Y., Kim, J. H., Kim, S. K., Oh, M. J. and Jung, M. Y. (1994). Antioxidant activities of selected oriental herb extracts. **Journal of American Oil Chemists' Society**, **71** :633-640.

King, H., Aubert, R. E., Herman, W. H. (1998). Global burden of diabetes, 1995-2025. **Diabetes Care**, **21** :1414-1431.

Kissebah, A., Freedman, D., and Peiris, A. (1989). Health risk of obesity. **Medical Clinics of North America**, **73** :111-138.

Kohner, E. M., Aldington, S. J., Stratton, I. M., Manley, S. E., Holman, R. R. and Matthews, D. R. *et al.* (1998). United Kingdom Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. **Archives of Ophthalmology**, **116** :297–303.

Konno, S., Aynehchi, S., Dolin, D. J., Schwartz, A. M., Choudhury, M. S. and Tazakin, H. N. (2002). Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal Maitake mushroom [*Grifola frondosa* (Dicks.:Fr.) S.F.Gray]. **International Journal of Medicinal Mushrooms**, **4** :185-95.

Krasnopolskaya, L. M., Makeeva, A. P., Lvova, N. A., Abramova, E. A. and Kodjina, E. V. (1998). Macromycetes – new producers of inhibitor of cholesterol biosynthesis lovastatin. In: **Proceedings 6th International Mycology Congress**. IMC, Jerusalem, p. 165

Kumaran, A. and Karunakaran, R. J. (2006). Antioxidant and free radical scavenging activity of aqueous extracts of *Coleus aromaticus*. **Food Chemistry**, **97** :09-114.

Kurihara, H., Fukami, H., Kusumoto, A., Toyoda, Y., Shibata, H., Matsui, Y., Asami, S., and Tanaka, T. (2003). Hypoglycemic action of *Cyclocarya paliurus* (Batal.) Iljinskaja in normal and diabetic mice. **Bioscience Biotechnology and Biochemistry**, **67** :877-880.

Kusano, S., Abe, H. and Tamura, H. (2001). Isolation of antidiabetic components from white-skinned sweet potato (*Ipomoea batatas* L.). **Bioscience, Biotechnology and Biochemistry**, **65** :109–114.

- Kuzuya, T. and Matsuda, A. (1982). Family histories of diabetes among Japanese patients with type 1 (insulin-dependent) and type 2 (non-insulindependent) diabetes. **Diabetologia**, **22(5)** :372–374.
- Lampe, J. W. (1999). Health effects of vegetables and fruits; assessing mechanisms of action in human experimental studies. **American Journal of Clinical Nutrition**, **70** :475S-490S.
- Laranjinha, J. Vieira, O., Madeira, V., and Almeida, L. (1995). Two related phenolic antioxidants with opposite effects on vitamin E content in low density lipoproteins oxidized by ferrylmyoglobin: consumption versus regeneration. **Archives of Biochemistry and Biophysics**, **323** :373-381.
- Lee, A., Thurnham, D. I., and Chopra, M. (2000). Consumption of tomato products with olive oil but not sunflower oil increases the antioxidant activity of plasma. **Free Radical, Biology and Medicine**, **29** :1051–1055.
- Liljenquist, J. E., Mueller, G. L., Cherrington, A. D., Perry J. M. and Rabinowitz D. (1979). Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man. **The Journal Clinical Endocrinology and Metabolism**, **48(1)** : 171-175.
- Lindequist, U., Niedermeyer, T. H. J., and Julich, W. D. (2005). The pharmacological potential of mushrooms. **Evidence-based Complementary and Alternative Medicine**, **2** :285-299.
- Lyons, T. J. and Jenkins, A. J. (1997). Lipoprotein glycation and its metabolic consequences. **Current Opinion in Lipidology**, **8** :174-180.
- Ma, L. and Lin, Z. B. (1992). Effect of *Tremella* polysaccharide on IL-2 production by mouse splenocytes. **Yaoxue Xuebao**, **27(1)** :1 –4.
- Madhavi, D. L., Singhal, R. S., and Kulkarni, P. R. (1996). Technological aspects of food antioxidants. In: Madhavi, D. L., Deshpande, S. S., and Salunkhe (Eds.). **Food Antioxidants: Technological Toxicological And Health Perspectives**. (pp. 159-265). Marcel Dekker, New York.
- Madsen, H. L., Andersen, C. M., Jorgensen, L.V. and Skibsted, L. H. (2000). Radical scavenging by dietary flavonoids. A kinetic study of antioxidant efficiencies. **European Food Research and Technology**, **211** :240–6.
- Mandrup-Poulsen, T. (1998). Diabetes. **British Medicinal Journal**, **316** :1221-1225.
- Manohar, V., Talpur, N. A., Echard, B. W., Lieberman, S., and Preuss, H. G. (2002). Effects of a water-soluble extract of Maitake mushroom on circulating glucose/insulin concentration in KK mice. **Diabetes, Obesity and Metabolism**, **4** :43-48.
- Marra, G., Cotroneo, P., Pitocco, D., Manto, A., Di Leo, M. A., Ruotolo, V., Caputo, S., Giardina, B., Ghirlanda, G. and Santini, S. A. (2002). Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. **Diabetes Care**, **25** :370-375.

- Martinez-Carrera, D., Morales, P., and Sobal, M. (1991). Sexual fruiting bodies from Symbiotes in *Pleurotus smithii*. **Mycological and Neotropical. Application**, **4** :9-18.
- Martin, A. M. (1992) Study of the growth and biomass composition of the edible mushroom *Pleurotus ostreatus*. In: **Developments in Food Science**. Food science and human nutrition. pp. 239-248.
- Martin-Gallan, P, Carrascosa, A., Gussinye, M., Dominguez, C. (2003). Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. **Free Radical Biological Medicine**, **34** :1563-1574.
- Mau, J. L., Chang, C. N., Huang, S. J. and Chen, C. C. (2003). Antioxidant properties of methanolic extracts from *Grifola frondosa*, *Morchella esculenta* and *Termitomyces albuminosus* mycelia. **Food Chemistry**, **29** :112-115.
- Mau, J. L., Chao, G. R., and Wu, K. T. (2001). Antioxidant properties of methanolic extracts from several ear mushrooms. **Journal of Agricultural and Food Chemistry**, **49** :5461-5467.
- Mau, J. L., Lin, Y. P., Chen, P. T., Wu, Y. H., Peng, J. T. (1998). Flavor compounds in king oyster mushrooms *Pleurotus eryngii*. **Journal of Agriculture and Food Chemistry**, **46** :4587-4591
- Mau, J. L., Lin, H. C., and Song S. F. (2002). Antioxidant properties of several speciality mushrooms. **Food Research International**, **35** :519-526.
- Mau, J. L., Tsai, S. Y., Tseng, Y. H., and Huang, S. J. (2005). Antioxidant properties of hot water extracts from *Ganoderma tsugae* Murrill. **LWT-Food Science and Technology**, **38** :587-589.
- Mazza, G., Kay, C. D., Cottrell, T., and Holub, B. J. (2002). Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. **Journal of Agriculture and Food Chemistry**, **50** :7731-7737.
- McCulloch, D. K., Raghu, P. K., Johnston, C., Klaff, L. J., Kahn, S. E., Beard, J. C., Ward, W. K., Benson, E. A., Koerker, D. J. and Bergman, R. N. (1988). Defects in beta-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: a model of preclinical insulin-dependent diabetes. **Journal of Clinical Endocrinology and Metabolism**, **67(4)** :785-792.
- Miles, P. G. and Chang, S. T. (1997). **Mushroom Biology: Concise Basics and Current Development**. World Scientific Publishing Company, New York.
- Misaki, A., Kishida, E., Kakuta, M., and Tabata, K. 1993. Antitumor fungal (1→3)-β-D- glucans: Structural diversity and effects of chemical modification. In: **Carbohydrates and Carbohydrate Polymers**. (ed.) Yalpani M. ATL Press. Mount Prospect, Illinois USA, pp.116-129.
- Mizuno, T., Wasa, T., Ito, H., Suzuki, C., and Ukai, N. (1992). Antitumor-active polysaccharides isolates from the fruiting body of *Hericium erinaceum*, an edible and medicinal mushroom called yamabushitake or hootou. **Bioscience Biotechnology and Biochemistry**, **56** :347-348.

- Mizuno, T. and Zhuang, C. (1995). Maitake, *Grifola frondosa*: pharmacological effects. **Food Reviews International**, **11(1)** :135-149.
- Mizuno, T., Zhuang, C., Abe, K., Okamoto, H., Kiho, T., Ukai, S., Leclerc, S. and Meijer, L. (1999a) Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of *Inonotus obliquus* (Pers.: Fr.) Pil. (Aphyllorphomycetideae). **International Journal of Medicinal Mushrooms**, **1** :301–316
- Mizuno, T., Minato, K., Ito, H., Kawade, M., Terai, H. and Tsuchida, H. (1999b). Antitumor polysaccharide from the mycelium of liquid-cultured *Agaricus blazei* Murrill. **Biochemistry and Molecular Biology International**, **47** :707–714
- Morais, H., Ramos, C., Matos, N., Forgacs, E., Cserhati, T., Almeida, V., Oliveira, J., Darwish, Y. and Illes, Z. (2002). Liquid chromatographic and electrophoretic characterisation of extracellular β -glucosidase of *Pleurotus ostreatus* grown in organic waste. **Journal of Chromatography**, **770** :111–119.
- Mori, H. (1987). Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. **International Journal of Immunopharmacology**, **9** :881-882.
- Muller, F. L., Lustgarten, M. S., Jang, Y., Richardson, A. and Van Remmen, H. (2007). Trends in oxidative aging theories. **Free Radical Biology and Medicine**, **43** :477-503.
- Murali, B. and Goyal, R. K. (2002), Effect of chronic treatment with losartan on streptozotocin induced diabetic rats. **Indian Journal of Experimental Biology**, **40(1)** :31-34.
- Nabulsi, A. A., Folsom, A. R., Heiss, G., Weir, S. S., Chambless, L. E., Wadson, R. L., and Eckfeldt, J. H. (1995). Fasting hyperinsulinemia and cardiovascular risk factors in non-diabetic adults: stronger associations in lean vs. obese subjects. **Metabolism**, **44** :914-922.
- Nanba, H., Hamaguchi, A. and Kuroda, H. (1987). The chemical structure of an antitumor polysaccharide in fruit bodies of *Grifola frondosa* (Maitake). **Chemical and Pharmacological Bulletin (Tokyo)**, **35** :1162–1168.
- Negi, P. S., and Jayaprakasha, G. K. (2003). Antioxidant and antibacterial activities of *Punica granatum* peel extracts. **Journal of Food Science**, **68** :1473-1477.
- Nerup, J., Mandrup-Poulsen, T., Molvig, J., Helqvist, S., Wogensens, L. and Egeberg, J. (1988). Mechanisms of pancreatic β -cell destruction in type I diabetes. **Diabetes Care**, **11(1)** :16–23.
- Niemeyer, H. B. and Metzler, M. (2003). Differences in the antioxidant activity of plant and mammalian lignans. **Journal Food Engineering**, **56** :255-256.
- Nigris, F., Lerman, L. O., Ignarro, S. W., Sica, G. and Lerman, A. (2003). Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. **Proceedings of the National Academy of Sciences of the United States of America**, **100** :1420– 1425.

- Oguri, S., Ando, A., and Nagata, Y. (1996). A novel developmental stage-specific lectin of the basidiomycete *Pleurotus cornucopiae*. **Journal of Bacteriology**, **178** (19) :5692-5698.
- Ohira, I. (1990). A revision of the taxonomic status of *Pleurotus citrinopileatus*. **Republic Tottori Mycological Institute**, **28** :143-150.
- Ohtsuka, S., Ueno, S., Yoshikumi, C., Hirose, F., Ohmura, Y., Wada, T., Fujii, T. and Takahashi, E. (1977) Polysaccharides and method for producing them from species of *Basidiomycetes*. UK Patent 1331513, 26 September 1973.
- Organization for Economic Cooperation and Development (OECD). (2000). **Guideline For The Testing Of Chemicals**. Revised Drafts Guideline 423: Acute oral toxicity-Acute toxic class method.
- Othman, A., Ismail, A., Abdul Ghani, N., and Adenan, I. (2007). Antioxidant capacity and phenolic content of cocoa beans. **Food Chemistry**, **100** :1523-1530.
- Packer, L., and Ong, A. S. H. (Eds.) (1997). **Biological Oxidants And Antioxidants: Molecular Mechanisms and Health Effects**. AOCS Press, Champaign, Illinois.
- Palmer, J. P. and Lernmark, Å. (1990). Pathophysiology of type 1 (insulin-dependent) diabetes. In: Rifkin H, Porte D, eds. **Diabetes Mellitus**. New York, NY: Elsevier. 414–435.
- Panneerselvam, R. S., and Govindaswamy, S. (2002). Effect of sodium molybdate on carbohydrate metabolizing enzymes in alloxan-induced diabetic rats. **Journal of Nutritional Biochemistry**, **13** :21-26.
- Patane, G., Piro, S., Anello M., Rabuazzo, A. M., Vigneri, R., and Purrello, F. (2000). Exposure to glibenclamide increases rat beta cells sensitivity to glucose. **British Journal of Pharmacology**, **129** :887-892.
- Pellegrini, N., Mauro, S., Colombi, B., Del Rio, D., Sara, S., Bianchi, M., Brighenti, B. (2003), Total Antioxidant Capacity of Plant Foods, Beverages and Oils Consumed in Italy Assessed by Three Different In Vitro Assays. **Journal of Nutrition**, **133** :2812-2819.
- Pizzichini, M., Fonzi, M., Sugherini, L., Fonzi, L., Gasparoni, A., Comporti, M. and Pompella, A. (2002). Release of mercury from dental amalgam and its influence on salivary antioxidant activity. **Science of the Total Environment**, **284(1-3)** :19-25.
- Pointing, S. B., Jones, E. B. G. and Vrijmoed, L. L. P. (2000). Optimization of laccase production by *Pycnoporus sanguineus* in submerged liquid culture. **Mycologia**, **92** :139–144.
- Poli, G., Albano, E. and Dianzani, M. U. (1987). The role of lipid peroxidation in liver damage. **Chemistry and Physics of Lipids**, **45** :117-142.
- Porte, D. (1991). B cells in type 2 diabetes mellitus. **Diabetes**, **40** :166-180.

Prager, R., Scherthaser G., and Graf H. (1986). Effect of metformin on peripheral insulin sensitivity in non-insulin dependent diabetes mellitus. **Diabète et Metabolisme**, **12** :346-350.

Quimio, T. H. (1986). Culturing *Ganoderma* the “*Pleurotus* way”. Mushroom Newsletter. **Tropics**, **6** :716-717.

Rahman, M. F., Siddiqui, M. K. J. and Jamil, K., (2001). Effects of vepacide (*Azadirachta indica*) on aspartate and alanine aminotransferase profiles in ubchronic study with rats. **Human and Experimental Toxicology**, **20** :243-249.

Ramarathnam, N., Osawa, T., Ochi, H., and Kawakishi, S. (1995). The contribution of plant food antioxidants to human health. **Trends in Food Science and Technology**, **6** :75-82.

Raper, C.A. (1978a). Sexuality and breeding. In: Chang, S. T. & Hayes, W. A. (Eds.). **The Biology and Cultivation of Edible Mushroom**. (pp. 83-117). Academic Press Inc., New York.

Reaven, G. M. (1998). The role of insulin resistance in human disease. **Diabetes**, **37** :1595-1607.

Revers, R. R., Fink, R., Griffin, J., Olefsky, J. M. and Kolterman, O. G. (1984). Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. **Journal of Clinical Investigation**, **73(3)** :664–672.

Rice-Evans, C. A., Miller, N. J. and Paganga, G. (1996). Structure antioxidant activity relationships of flavonoids and phenolic acids. **Free Radical Biology and Medicine**, **20** :933-956.

Richard, A. A. and Polansky, M. M. (2002). Tea enhances insulin activity. **Journal of Agriculture and Food Chemistry**, **50** :7182-7186.

Richter, B., and Neises, G. (2003). “Human” insulin versus animal insulin in people with diabetes mellitus. **Cochrane Database System Review**, **3** :CD113816.

Rolo, A. P. and Palmeira, C. M. (2006) Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. **Toxicology and Applied Pharmacology**, **212** :167-178.

Rosado, F. R., Kimmelmeier, C. and Da Costa, S. M. G. (2002). Alternative method of inoculum and spawn production for the cultivation of the edible Brazilian mushroom *Pleurotus ostreatoroseus*. **Journal of Basic Microbiology**, **42(1)** :37-44.

Rosenfeld, L. (1989) Atherosclerosis and the cholesterol connection: revolution of a clinical application. **Clinical Chemistry**, **35** :521–531.

Rosen, P., Nawroth, P. P., King, G., Moller, W., Tritschler H. J., and Packer, L. (2001). The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. **Diabetes Metabolism Research Review**, **17** :189-212.

- Sarangi, I., Ghosh, D., Bhutia, S. K., Mallick, S. K., Maiti T. K. (2006). Anti-tumor and immunomodulating effects of *Pleurotus ostreatus* mycelia-derived proteoglycans. **International Immunopharmacology**, **6** :1287–1297.
- Sato, Y., Hotto, N., Sakamoto, N., Matsuoka, S., Ohishi, N., and Yafi, K. (1979). Lipid peroxide level in plasma of diabetic patients. **Biochemical Medicine**, **2** :104-107.
- Sheng, J. H. and Chen, Q. H. (1989). Antilipemic effect of polysaccharides from *Auricularia aurantia*, *Tremella fuciformis* and *Tremella fuciformis* spores. **Journal of China Pharmaceutical University**, **20** :344-347.
- Sies, H. (1997). Oxidative stress: oxidants and antioxidants. **Experimental Physiology**, **82** :291-295.
- Sindhu, R. K., Koo, J. R., Roberts, C. K. and Vaziri, N. D. (2004). Dysregulation of Hepatic Superoxide Dismutase, Catalase and Glutathione Peroxidase in Diabetes: Response to Insulin and Antioxidant Therapies. **Clinical and Experimental Hypertension**, **26(1)** :43–53.
- Singer, R. (1978). Hallucinogenic mushrooms. In: Rumark, B. H. and Salzman, E. (Eds.). **Mushroom Poisoning Diagnosis and Treatment**. CRC Press, Palm Beach.
- Singleton, V. L., Orthofer, R., and Lamuela-Raventos, R. M. (1999). Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. **Methods in Enzymology**, **299** :152-178.
- Shipp, J. C., Cunningham, R. W., Russell, R. O. and Marble, A. (1965). Insulin resistance: Clinical features, natural course and effects of adrenal steroid treatment. **Medicine (Baltimore)**, **44** :165-186.
- Skim, F., Lazrek, H. B., Kaaya, A., el Amri, H. and Jana, M. (1999). Pharmacological studies of two antidiabetic plants: *Globularia alypum* and *Zygophyllum gaetulum*. **Therapie**, **54(6)** :711-5.
- Solomko, E. F., Eliseeva, G. S. (1988). Biosynthesis of vitamins B by fungus *Pleurotus ostreatus* in a submerged culture. **Prikladnaya Biokhimiya i Mikrobiologiya**, **24** :164-169.
- Sommers, C. H., Fan, X., Niemira, B. A. and Sokorai, K. J. (2003). Radiation (Gamma) resistance and post-irradiation growth of *listeria monocytogenes* suspended in beef bologna that contained sodium diacetate and potassium lactate. **Journal Of Food Safety**, **66** :2051-2056.
- Song, Y. S., Kim, S. H. Sa, Jin, C., Lim, C. J., and Park, E. H. (2003). Anti-angiogenic, antioxidant and xanthine oxidase inhibition activities of the mushroom *Phellinus linteus*. **Journal of Ethnopharmacology**, **88** :113-116.
- Spiro, R. G. (1973). Biochemistry of the renal glomerular basement membrane and its alterations in diabetes mellitus. **New England Journal of Medicine**, **288** :1337–1342.
- Spiteller, G. (2001). Peroxidation of linoleic acid and its relation to aging and age dependent diseases. **Mechanisms of Ageing Devices**, **122** :617-657.

Srikanta, S., Ricker, A. T., McCulloch, D. K., Soeldner, J. S., Eisenbarth, G. S. and Palmer, J. P. (1986). Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. **Diabetes**, **35(2)** :139–142.

Stamets, P. (1995). **Growing Gourmet and Medicinal Mushroom**. Ten Speed Press, Berkeley.

Stavinoha, J., Slana, S., Weintraub, P., Mobley (1991), The antiinflammatory activity of *Ganoderma lucidum*. **Third International Symposium on *Ganoderma lucidum*** :9-21.

Su, J. F., Guo, C. J., Wei, J. Y., Yang, J. J., Jiang, Y. G., and Li, Y. F. (2003). Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. **Biomedical and Environmental Sciences**, **16** :1-8.

Sun, T. and Ho, C. T. (2005). Antioxidant activities of buckwheat extracts. **Food Chemistry**, **90** :743-749.

Suzuki, W. and Ikegawa, T. (1998). Anti-cancer substance emitanin. Japan Patent JP 53006494, 780120 Showa.

Swanston-Flatt, S. K., Day, C., Flatt, P. R., Gould, B. J., and Bailey C. J. (1989). Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. **Diabetes Research**, **10** :69-73.

Talpur, N. A., Echard, B. W., Dadgar, A., Aggarwal, S., Zhuang, C., and Bagchi, D. *et al.*, (2002). Effects of Maitake mushroom fractions on blood pressure of Zucker fatty rats. **Research Communications in Molecular and Pathological Pharmacology**, **112** :68-82.

Talpur, N. A., Echard, B. W., Fan, A. Y., Jaffari, O., Bagchi, D., and Preuss, H. G. (2002b). Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains. **Molecular and Cellular Biochemistry**, **237** :129-136.

Temple, N. J. (2000) Antioxidants and disease: more questions than answers. **Nutrition Research**, **20** :449-459.

Tsai, P. J., McIntosh, J. and Pearce, P. (2002). Anthocyanin and antioxidant capacity in Roselle (*Hibiscus Sabdariffa L.*) extract. **Food Research International**, **35** :351- 356.

Ukai, S., Hirose, K., Kiho, T., Hara, C, Irikura, T. (1972). Antitumor activity on sarcoma 180 of the polysaccharides from *Tremella fuciformis* Berk. **Chemical & Pharmaceutical Bulletin**, **20** :2293–2294.

Unger, R. H. and Grundy, S. (1985). Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. **Diabetologia**, **28** :119-125.

Uysal, N., Yalaz, G., Acikgov, O., Gonenc, S., and Kayatekin, B. M. (2005). Effect of L-carnitine on diabetogenic action of streptozotocin in rats. **Neuroendocrinology Letters**, **4(26)** :421-422.

- Van-Acker, S. A. B. E., Van-Balen, G. P., van-den-Berg, D. J., Bast, A., and Van-Der-Vijgh, W. J. F. (1998). Influence of iron chelation on the antioxidant activity of flavonoids. **Biochemical Pharmacology**, **56** :935-943.
- Velioglu, Y. S., Mazza, G., Gao, L., and Oomah, B. D. (1998). Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. **Journal of Agriculture and Food Chemistry**, **46** :4113-4117.
- Vincent, A. M., Brownlee, M., and Russell J. W. (2002). Oxidative stress and programmed cell death in diabetic neuropathy. **Annals of New York Academy of Science**, **959** :368-383.
- Von Meyenburg, H. (1940). Ober insulitis' bei diabetes. Schweizerische medizinische wochenschrift. **Journal Suisse de Medecine**, **70** :554.
- Wang, H., Gao, J. and Ng, T. B. (2000). A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom *Pleurotus ostreatus*. **Biochemistry, Biophysics and Reserve Communication**, **275** :810–816.
- Wang, J. C., Hu, S. H., Liang, Z. C. and Yeh, C. J (2005). Optimization for the production of water-soluble polysaccharide from *Pleurotus citrinopileatus* in submerged culture and its antitumor effect. **Applied Microbiology and Biotechnology** **67** :759–766.
- Wang, N., Shen, F., Tan, Q., Chen, M. and Pan, Y. (2000). Detecting in 9 extracellular enzyme activities of *Agrocybe aegerita* strains. **Mycosystema**, **19** :540–546.
- Wang, W. S. and Wang, D. H. (1997). Enhancement of the resistance of tilapia and grass carp to experimental *Aeromonas hydrophila* and *Edwardsiella ictaluri* infections by several polysaccharides. **Comparative Immunology, Microbiology and Infectious Diseases**, **20** :261–270.
- Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B. and Porte, D., Jr. (1984). Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. **Journal of Clinical Investigation**, **74**(4) :1318–1328.
- Wasser, S. P., Nevo E., Sokolov D., Reshetnikov S., and Timor-Tismenetsky M. (2000). Dietary supplement from medicinal mushrooms: Diversity of types and variety of regulations. **International Journal of Medicinal Mushrooms**, **2** :1-19.
- Wasser, S. P. and Weis, A. L. (1997b). Reishi mushroom [*Ganoderma lucidum* (Curt.: Fr.) P.Karst.]. In: Nevo E (ed.) **Medicinal Mushrooms**. Peledfus, Haifa, Israel.
- Wasser, S. P., and Weis, A. L. (1999). Medicinal properties of substances occurring in higher basidiomycetes mushrooms. **International Journal of Medicinal Mushrooms**, **1** :31-62.
- Watkins, B., Shen, C., Allen, K. and Seifert, M. (1996). Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE₂ biosynthesis, tissue IGF-1 levels, and bone morphometry in chicks. **Journal of Bone and Mineral Research**, **11** :1321-1332.

- West, I. C. (2000). Radicals and oxidative stress in diabetes. **Diabetic Medicine**, **17** :171-180.
- Wildholz, M. (1983). The Merck index: **An Encyclopedia of Chemicals, Drugs and Biologicals**. 10th Edition, Merck & Co., New Jersey.
- Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global prevalence of diabetes. **Diabetes Care**, **27** :1047-1053.
- Willet, W. C. (1994). Diet and health: What should we eat? **Science**. 22.
- Wisbeck E., Robert A. P. and Furlan S. A. (2002). Rating production of antimicrobials by fungi the genus *Pleurotus*. **Health and Environment Journal**, **3(2)** :7-10.
- Wong, K. H., Sabaratnam, V., Abdullah, N., Kuppusamy, U. R., and Naidu, M. (2009). Effect of cultivation techniques and processing on antimicrobial and antioxidant activities of *Hericium erinaceus* (Bull.:Fr.) Pers. extract. **Food Technology and Biotechnology**, **47(1)** :47-55.
- Xie, J. T., Aung, H. H., Wu, J. A., Attele, A. S. and Yuan, C. S. (2002). Effects of american ginseng berry extract on blood glucose levels in *ob/ob* mice. **American Journal of Chinese Medicine**, **30** :187-194.
- Yakovlev, A. Y., Borovskii, G. B., Voinikov, V. K., Grabelnych, O. I., Pobezhimova, T. P., and Antipina, A. I. (2002). An effect of water-soluble proteins of fungi differed in frost-hardy on the energetic activity of isolated plant mitochondria. **Journal of Thermology and Biology**, **27** :239-244.
- Yalow, R. S., and Berson, S. A. (1960). Immunoassay of endogenous plasma insulin in man. **Journal of Clinical Investigation**, **39** :1157-1162.
- Yang, J. H., Lin, H. C., and Mau, J. L. (2002). Antioxidant properties of several commercial mushrooms. **Food Chemistry**, **77** :229-235.
- Yang, Q. Y., and Jong, S.C., (1989). Medicinal mushrooms in China. **Mushroom Science**, **12** :631-643
- Yki-Jarvinen, H. (1992). Glucose toxicity. **Endocrinology Review**, **13** :415-431.
- Yoshikawa, T., Toyokuni, S., Yamamoto, Y., and Naito, Y. (Eds.) (2000). **Free Radicals in Chemistry Biology and Medicine**. OICA International, London, U. K.
- Yui, T., Ogawa, K., Kakuta, M. and Misaki, A. (1995). Chain conformation of a glucoronyloxylomannan isolated from fruit body of *Tremella fuciformis* Berk. **Journal of Carbohydrate Chemistry**, **14** :255-263.
- Yu, L., Haley, S., Peret, J., Harris, M., Wilson, J., and Qian, M. (2002). Free radical scavenging properties of wheat extracts. **Journal of Agricultural and Food Chemistry**, **50** :1619-1624.

Zadrazil, F. (1978). Cultivation of *Pleurotus*. In: Chang, S. T. & Hayes, W. A. (Eds.): **The Biology and Cultivation of Edible Mushroom**. (pp. 521-557) Academic Press Inc., New York.

Zeisel, S. H. (1999). Regulation of "Nutraceuticals". **Science**, **285(5435)** :1853-1855.

Zhang, L., Fei, S. and Zhang, Y. (1994a). The influence of chemical modification on antiviral (CB5) activity of polysaccharide from *Pleurotus citrinopileatus*. **Sheng Wu Hua Hsueh Zazhi**, **10** :150–154

Zhuang, C. and Mizuno, T. (1999). Biological responses from *Grifola frondosa* (Dick.: Fr.) SF Gray-Maitake (Aphyllorphomycetidae). **International Journal of Medicinal Mushrooms**, **1** :317-324.

Zidayeh, F. N. and Cohen, M. P. (1993). Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. **Molecular and Cellular Biochemistry**, **125** :19-25.

Zimmet, P. Z. (1999). Diabetes epidemiology as a tool to trigger diabetes research and care. **Diabetologia**, **45(5)** :499-518.

APPENDICES

APPENDIX A: MEDIA AND BUFFER

1) MEDIA

A) Glucose-yeast-malt-peptone agar (GYMP Agar)

Nutrient	Concentration of nutrients (g/400 ml)
Magnesium sulphate heptahydrate (MgSO ₄ ·7H ₂ O)	0.40
Potassium dihydrogen orthophosphate (KH ₂ PO ₄)	0.40
Potassium phosphate dibasic (anhydrous) (K ₂ HPO ₄)	0.40
Ammonium chloride pure (NH ₄ Cl)	0.40
Glucose	6.00
Peptone	3.20
Malt Extract	3.20
Yeast Extract	3.20
Agar	7.00
Chloramphenicol	0.04

The nutrients was dissolved on 400 ml of distilled water and sterilized in an autoclave for 20 minutes at 15 psi, 121°C.

B) Glucose-yeast-malt-peptone liquid medium (GYMP Liquid Medium)

To prepare GYMP liquid medium, all nutrients to prepare GYMP agar was used except for agar.

2) BUFFER

A) 0.1 M Citrate buffer, pH 4.5

To prepare 1 M citric acid solution, 210.14 g of citric acid was added to 1000 ml of sterilized distilled water. To prepare 1 M of sodium citrate solution, 294.12 g of sodium citrate was added to 1000 ml of sterilized distilled water. To prepare 0.1 M citrate buffer, 19 ml of 1 M citrate acid solution was added to 81 ml of 1 M sodium citrate solution and the final volume was added up to 1000 ml in volumetric flask. The pH 4.5 was adjusted by adding a small amount of sodium hydroxide to increase the pH and citrate acid to lower the pH.

B) Phosphate buffer saline

8.0 g of sodium chloride (NaCl), 0.2 g of potassium chloride (KCl), 1.44 g of sodium hydrogen phosphate (Na_2HPO_4) and 0.2 g of potassium dihydrogen orthophosphate (KH_2PO_4) were suspended in 1000 ml of distilled water. The solution was filtered with Whatman No. 1 Filter Paper and autoclaved for 20 minutes at 15 psi, 121°C.

C) 10 % formalin (Formaldehyde)

10 ml of formaldehyde was suspended in 90 ml of distilled water.

D) Normal saline

9.0 g of sodium chloride was suspended in 1000 ml of distilled water and the solution was filtered with Whatman No. 1 Filter Paper.

E) 70 % alcohol

70 ml of 100 % alcohol was mixed with 30 ml of distilled water.

F) 85 % alcohol

85 ml of 100 % alcohol was mixed with 15 ml of distilled water.

G) 0.2 % hydrochloric acid (HCl)

0.56 ml of 36 % HCl was added to volumetric flask and the final volume was made up to 100 ml with distilled water.

H) 0.2 % sodium carbonate (NaHCO_3)

0.2 g of sodium carbonate was dissolved in 100 ml of distilled water and filtered with Whatman No. 1 Filter Paper.

APPENDIX B: ANALYTICAL TECHNIQUES

1) Determination of total phenolic content (Singleton *et al.*, 1999)

Reagents

10% Folin-Ciocalteu, 10% sodium carbonate (Na_2CO_3) solution and gallic acid (3,4,5-trihydroxybenzoic acid) stock solution.

Preparation of reagents

a) 10% Folin-Ciocalteu

10 ml of Folin-Ciocalteu was added to 90 ml of sterilized distilled water. This mixture was prepared in a dark bottle as Folin-Ciocalteu is light sensitive.

b) 10% sodium carbonate solution (Na_2CO_3)

20 g of AR grade anhydrous sodium carbonate salt was dissolved in 200 ml of sterilized distilled water. The solution was stirred and heated until all the salt was completely dissolved. The solution was filtered and stored in bottle at room temperature.

c) Gallic acid stock solution


The gallic acid stock solution used was 1%. A series of dilution was prepared to obtain this stock solution. 10 mg of gallic acid was mixed in 1 ml of methanol and this was known as basic mixture. 1ml was taken from basic mixture and mixed with 9 ml of methanol. This method was repeated twice and the final concentration was $10\mu\text{g/ml}$ and this was known as stock solution.

Procedure for preparation of gallic acid calibration plot

A calibration plot, using gallic acid concentration with concentration ranging from 0 to $10\mu\text{g/ml}$ was prepared. Gallic acid stock solution in volumes ranging from $50\mu\text{l}$ to $250\mu\text{l}$ were pipetted out into test tubes. The final volume was made to $250\mu\text{l}$ with methanol in each test tube. $250\mu\text{l}$ of different concentrations of gallic acid solution and negative control (methanol was used instead of gallic acid) were mixed with $250\mu\text{l}$ of 10% Folin-Ciocalteu. After 3 minutes of incubation, $500\mu\text{l}$ of 10% sodium carbonate solution was added to the mixture. The reaction mixtures were incubated at 37°C in dark condition for 1 hour. The blank contained only methanol. The absorbance was determined at 750 nm with a spectrometer. The gallic acid calibration plot was obtained by plotting the absorbance against concentration of the gallic acid ($\mu\text{g/ml}$).

The table below summarizes the preparation of different concentrations of gallic acid solution for calibration plot:

Gallic Acid ($\mu\text{g/ml}$)	Gallic Acid Stock Solution (μl)	Methanol (μl)
0	0.00	250.00
2	50.00	200.00
4	100.00	150.00
6	150.00	100.00
8	200.00	50.00
10	250.00	0.00



Gallic acid calibration plot

Determination of total phenolic content in mycelial extract and positive control

The absorbance value of the mycelial extract and Quercetin after subtraction of negative control was translated into total phenolic content [$\mu\text{g/ml}$ of gallic acid equivalents (GAEs)] using gallic acid calibration plot with the following formula:

$$\text{Total phenolic content } (\mu\text{g/ml of GAEs}) = \frac{(y + 0.0269)}{0.0556}$$

2) Scavenging activity on 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical (Cheung *et al.*, 2003).

Reagents

a) DPPH solution (0.8%)

0.08 g of DPPH was dissolved in 10 ml of methanol. The solution was mixed thoroughly until the DPPH was completely dissolved.

b) Quercetin stock solution


The Quercetin stock solution was prepared by dissolving 20 mg of Quercetin in 10 ml of methanol. The solution was mixed until Quercetin was completely dissolved in methanol.

Procedure for preparation of Quercetin as positive control for scavenging activity on DPPH radical

A positive control plot, using Quercetin with concentrations ranging from 0.005 mg/ml to 0.05 mg/ml was prepared. The Quercetin stock solution ranging from 0.01 to 0.1 ml and negative control (3.9 ml of methanol) were pipetted out into cuvettes. The final volume was made with methanol. 0.1 ml of DPPH solution was added into each cuvettes. The reaction mixtures were mixed and incubated for 30 minutes at room temperature. The blank contain only 4 ml of methanol. The absorbance was determined at 520 nm with a spectrophotometer.

Table below summarizes the experimental procedures for Quercetin:

Quercetin (mg/ml)	Quercetin stock solution (ml)	Methanol (ml)	DPPH solution (ml)
0	0	3.900	0.100
0.005	0.010	3.890	0.100
0.010	0.020	3.880	0.100
0.015	0.030	3.870	0.100
0.020	0.040	3.860	0.100
0.025	0.050	3.850	0.100
0.030	0.060	3.840	0.100
0.035	0.070	3.830	0.100
0.040	0.080	3.820	0.100
0.045	0.090	3.810	0.100
0.050	0.100	3.800	0.100




Scatter plot of scavenging effect of Quercetin on DPPH radical to determine EC₅₀ value.

Scavenging activity of mycelial extract on DPPH radical


A stock of mycelial extract in methanol with concentration of 20 mg/ml was prepared and assayed as following method summarized in table below.

Table below summarizes the experimental procedures for mycelial extracts:


Mycelial extract (mg/ml)	Mycelial extract stock solution (ml)	Methanol (ml)	DPPH solution (ml)
0	0	3.90	0.10
0.25	0.05	3.85	0.10
0.30	0.06	3.84	0.10
0.35	0.07	3.83	0.10
0.40	0.08	3.82	0.10
0.45	0.09	3.81	0.10
0.50	0.10	3.80	0.10




Scatter plot of scavenging effect of mycelial extract of *P. sajor caju* (KUM 50084) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. eryngii* (KUM 50087) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. ostreatus* (KUM 50089) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. sapidus* (KUM 50090) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. flabellatus* (KUM 50091) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. hungarian* (KUM 50092) on DPPH radical for determination of EC50 value by extrapolation of graph.




Scatter plot of scavenging effect of mycelial extract of *P. citrinopileatus* (KUM 50093) on DPPH radical for determination of EC50 value by extrapolation of graph.



Scatter plot of scavenging effect of mycelial extract of *P. cystidiosus* (KUM 50094) on DPPH radical for determination of EC50 value by extrapolation of graph.



Scatter plot of scavenging effect of mycelial extract of *P. florida* (KUM 50213) on DPPH radical for determination of EC50 value by extrapolation of graph.



Scatter plot of scavenging effect of *Quercetin* on DPPH radical for determination of EC50 value by extrapolation of graph.

3) Ferric reducing antioxidant power (FRAP) assay (Benzie & Strain, 1996, 1999)

Reagents

10 mmol/l 2,4,6-tripyridyl-s-triazine (TPTZ), 40 mmol/l hydrochloric acid (HCl), 20 mmol/l ferric chloride ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$), sodium acetate trihydrate ($\text{CH}_3\text{COONa} \cdot 3\text{H}_2\text{O}$), glacial acetic acid (pure water-free acetic acid), 1000 μM ferrous sulphate ($\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$) stock solution.

Preparation of reagents

a) 300 mmol/l acetate buffer, pH 3.6

3.1 g of AR grade sodium acetate trihydrate salt was mixed with 16 ml of glacial acetic acid and distilled water was added until the final volume was 1 litre. The solution was mixed until all the salt was completely dissolved.

b) 10 mmol/l TPTZ in 40 mmol/l HCl

To prepare 100 ml of 40 mmol/l HCl, 0.33 ml of 12.08 N HCl was dissolved in distilled water in a 100 ml volumetric flask. The final volume was made to 100 ml with distilled water and shaken until HCl was completely mixed with distilled water. To prepare 30 ml of 10 mmol/l TPTZ in 40 mmol/l HCl, 0.0937 g of TPTZ was dissolved in 30 ml of 40 mmol/l HCl and mixed by vortex until all the salt was completely dissolved.

c) 20 mmol/l $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$

0.1622 g of AR grade $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ salt was dissolved in 30 ml of distilled water and mixed by vortex until all the salt was completely dissolved.

d) $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ stock solution

The $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ stock solution used was 1000 μM . 0.0278 g of AR grade $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ salt was dissolved in 100 ml of DMSO (dimethyl sulfoxide AR grade). The solution stirred until all the salt was completely dissolved.

e) FRAP working reagent

The FRAP working reagent was prepared by mixing 10 volumes of 300 mmol/l acetate buffer, pH 3.6, with 1 volumes of 10 mmol/l TPTZ in 40 mmol/l HCl and with 1 volume of 20 mmol/l $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$.


Procedure for preparation of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ calibration plot

A calibration plot using $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ with concentrations ranging from 100 to 1000 μM was prepared. 0.025 ml of different concentrations of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ solution was added


to wells of 96 well (0.3 ml) microtiter plate in quadruplicate. 0.175 ml of freshly prepared FRAP reagent was warmed at 37 °C and added to three of the samples, while the same volume of acetate buffer was added to the fourth well, (sample blank). The plate was placed in an automated microplate reader (Power wave X 340, Bio-Tek Instruments, Inc., Winooski, USA) and the absorbance was measured at 593 nm with temperature at 37 °C for 4 minutes. Absorbance values were measured and taken after 4 minutes. The absorbance at 4 minutes after starting the reaction (sample added) was selected as final reading (A_{sample}). Reagent blank reading, using 0.175 ml of FRAP reagent ($A_{\text{reagent blank}}$) and sample blank reading, using sample and acetate buffer ($A_{\text{sample blank}}$), were taken. The change in absorbance, between A_{sample} and ($A_{\text{reagent blank}} + A_{\text{sample blank}}$) was calculated. The $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ calibration plot was obtained by plotting the change in absorbance against concentration of the $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (μM). A new calibration plot was prepared for each 96 well microtiter plate that was ran as results may vary between plates.

Table below summarizes the preparation of different concentrations of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ solution for calibration plot:


$\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (μM)	$\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ stock solution (ml)	DMSO (ml)
100	1.0	9.0
200	2.0	8.0
300	3.0	7.0
400	4.0	6.0
500	5.0	5.0
600	6.0	4.0
700	7.0	3.0
800	8.0	2.0
900	9.0	1.0
1000	10.0	0.0



FeSO₄·7H₂O calibration plot



FeSO₄·7H₂O calibration plot



FeSO₄·7H₂O calibration plot

FRAP assay of mycelial extract and positive control

The mycelial extract and Quercetin were assayed and the change in absorbance was calculated following the method above. The change in absorbance value of the mycelial extract and Quercetin was obtained from the following formulas using the FeSO₄·7H₂O calibration plot:

$$\text{FRAP value } (\mu\text{M of FeSO}_4\cdot 7\text{H}_2\text{O equivalents}) = \frac{(y - 0.0522)}{0.0014}$$

$$\text{FRAP value } (\mu\text{M of FeSO}_4\cdot 7\text{H}_2\text{O equivalents}) = \frac{(y - 0.0544)}{0.0014}$$

$$\text{FRAP value } (\mu\text{M of FeSO}_4\cdot 7\text{H}_2\text{O equivalents}) = \frac{(y - 0.0544)}{0.0014}$$

APPENDIX C: ENZYMATIC TECHNIQUES

1) Insulin assay

The DSL-10-1600 ACTIVE® Insulin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of Insulin in serum or plasma. This Kit is an enzymatically amplified “one-step” sandwich-type immunoassay.

Reagents supplied

a) Anti-Insulin-Coated Microtitration Strips

One strip holder, containing 96 polystyrene microtiter wells with anti-insulin antibody immobilized to the inside wall of each well.

b) Insulin Standards (Lyophilized)

One vial labeled A, containing 0 $\mu\text{IU/mL}$ Insulin and four vials, labeled B-E, containing concentrations of approximately 3.0, 10.0, 50.0 and 100.0 $\mu\text{IU/mL}$ Insulin in human serum with a non-mercury preservative. Standard A was reconstituted with 1.0 ml of deionized water and Standards B-E with 0.5 mL of deionized water.

c) Insulin Controls (Lyophilized)

Two vials, Levels I and II, containing low and high concentrations of insulin in human serum with a non-mercury preservative. Each vial was reconstituted with 0.5 mL of deionized water.

d) Insulin Antibody-Enzyme Conjugate Concentrate

One vial, containing 0.3 mL of an anti-Insulin antibody conjugated to horseradish peroxidase in buffer with a non-mercury preservative and it was diluted prior to use in assay Buffer. (200 μL of the Insulin Antibody-Enzyme Conjugate Concentrate in 10 mL of the Assay Buffer).

e) Assay Buffer B

One bottle, 28 mL, containing a protein-based buffer with a non-mercury preservative.

f) TMB Chromogen Solution

One vial, 11 mL, containing a solution of tetramethylbenzidine (TMB) in citrate buffer with hydrogen peroxide.

g) Wash Concentrate

One bottle, 60 mL, containing buffered saline with a nonionic detergent. This concentrated buffered saline was diluted 25 fold with deionized water prior to use. (60 mL of Wash Concentrate added to 1500 mL of deionized water).

h) Stopping Solution


One vial, 11 mL, containing 0.2 M sulfuric acid.

i) Microtitration Wells

A 96 well plate with coated wells.

Materials Required But Not Supplied

- a) Microtitration plate reader capable of absorbance measurement at 450 nm.
- b) Deionized water
- c) Precision pipette to deliver 10, 25, and 100 μL
- d) Microtitration plate shaker capable of 500-700 orbital revolutions per minute (rpm)
- e) Absorbent materials for blotting the strips



Insulin Standard plot

Insulin assay of serum samples

The serum samples were assayed following the method described above. The absorbance values were translated into Insulin Level ($\mu\text{IU/ml}$) using the standard plot with the following formula:

$$\text{Insulin Level } (\mu\text{IU/ml}) = \text{ANTILOG} \left(\frac{(y + 1.4662)}{0.497} \right)$$

2) Catalase activity assay (Beers, 1952)

Reagents

100 unit of Catalase stock and 75 mM of hydrogen peroxide (H₂O₂).

Preparations of reagents

a) 100 unit of Catalase stock

4.4 mg of Catalase (2250 Unit/mg solid) was dissolved in 10 ml of phosphate buffer saline. This makes up a solution of 10000 unit of Catalase stock. This was then diluted to 1000 unit of Catalase by adding 1 ml of Catalase stock into 9 ml of sterilized distilled water.

b) 75 mM of H₂O₂


To prepare 50 ml of 75 mM H₂O₂, 2.13 ml of H₂O₂ (6% [w/v]) was added into 50 ml volumetric flask. The final volume was made to 50 ml by adding sterilized distilled water and shaken until all the H₂O₂ was completely mixed with sterilized distilled water.

Procedure for preparation of Catalase standard plot

A standard plot, using Catalase with concentrations ranging from 20 unit to 100 unit was prepared. The Catalase stock solution ranging from 0.02 to 0.10 ml and negative control (1 ml of 75 mM H₂O₂) were pipetted out into cuvettes. The final volume was made with sterilized distilled water. The reaction mixtures were mixed and incubated for 30 seconds at room temperature. The blank contain only 1 ml of sterilized distilled water. The absorbance was determined at 240 nm with a spectrophotometer. To determine the Catalase activity of serum samples, 0.1 ml of sample was added to 0.9 ml of 75 mM H₂O₂ and was assayed in triplicates.

Table below summarizes the experimental procedures for Catalase:

Catalase (1000 Unit)	Catalase stock solution (ml)	75 mM of H₂O₂ (ml)
0	0	1.00
20	0.02	0.98
40	0.04	0.96
60	0.06	0.94
80	0.08	0.92
100	0.10	0.90



Catalase standard plot

Catalase activity of serum samples

The serum samples were assayed following the method described above. The absorbance values were translated into Catalase unit (Unit/mg solid) using the standard plot with the following formula:

$$\text{Catalase activity (Unit/mg solid)} = \frac{(y - 0.0087)}{0.003}$$

3) Preparation of histological slides

Reagents

10% formaldehyde, normal saline, 70% alcohol, 85% alcohol, 95% alcohol, alcohol 100% terpeneol, terpeneol-paraffin (1:1), paraffin, Mayer's Albumin, xylene, distilled water, hematoxylin, 0.2% hydrochloric acid (HCl), 0.2% sodium bicarbonate (NaHCO₃), Eosin and Canada Balsam.

APPENDIX D: DATA AND STATISTICAL TABLES




Figure 1: Fasting insulin levels (µIU/mL) at 45 days.




Figure 2: Fasting blood glucose levels (mmol/L) at 45 days.




Figure 3: Body weight (gram) at 45 days.




Figure 4: Fasting catalase levels (U/mL) at 45 days.

Table 1: Descriptives: Total phenolic contents of mycelial extracts

Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
50084	3	210.2667	1.75024	1.01050	205.9188	214.6145	208.50	212.00
50087	3	194.1000	1.80000	1.03923	189.6286	198.5714	192.30	195.90
50089	3	195.9000	1.80000	1.03923	191.4286	200.3714	194.10	197.70
50090	3	218.0000	1.03923	.60000	215.4184	220.5816	217.40	219.20
50091	3	233.5333	3.60185	2.07953	224.5858	242.4808	230.00	237.20
50092	3	195.1000	.91652	.52915	192.8233	197.3767	194.10	195.90
50093	3	197.1000	1.03923	.60000	194.5184	199.6816	195.90	197.70
50094	3	209.5000	.91652	.52915	207.2233	211.7767	208.50	210.30
50213	3	194.7000	1.03923	.60000	192.1184	197.2816	194.10	195.90
Total	27	205.3556	13.22769	2.54567	200.1229	210.5883	192.30	237.20

Table 2: ANOVA: Total phenolic contents of mycelial extracts

Group	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	4494.393	8	561.799	184.286	.000
Within Groups	54.873	18	3.049		
Total	4549.267	26			

Table 3: Multiple comparisons: Total phenolic contents of mycelial extracts

(I) Group	(J) Group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval		
					Lower Bound	Upper Bound	
LSD	50084	50087	16.16667(*)	1.42560	.000	13.1716	19.1617
		50089	14.36667(*)	1.42560	.000	11.3716	17.3617
		50090	-7.73333(*)	1.42560	.000	-10.7284	-4.7383
		50091	-23.26667(*)	1.42560	.000	-26.2617	-20.2716
		50092	15.16667(*)	1.42560	.000	12.1716	18.1617
	50087	50093	13.16667(*)	1.42560	.000	10.1716	16.1617
		50094	.76667	1.42560	.597	-2.2284	3.7617
		50213	15.56667(*)	1.42560	.000	12.5716	18.5617
		50084	-16.16667(*)	1.42560	.000	-19.1617	-13.1716
		50089	-1.80000	1.42560	.223	-4.7951	1.1951
		50090	-23.90000(*)	1.42560	.000	-26.8951	-20.9049
		50091	-39.43333(*)	1.42560	.000	-42.4284	-36.4383
		50092	-1.00000	1.42560	.492	-3.9951	1.9951
		50093	-3.00000(*)	1.42560	.050	-5.9951	-.0049
		50094	-15.40000(*)	1.42560	.000	-18.3951	-12.4049
50089	50213	-.60000	1.42560	.679	-3.5951	2.3951	
	50084	-14.36667(*)	1.42560	.000	-17.3617	-11.3716	
	50087	1.80000	1.42560	.223	-1.1951	4.7951	
	50090	-22.10000(*)	1.42560	.000	-25.0951	-19.1049	
	50091	-37.63333(*)	1.42560	.000	-40.6284	-34.6383	
	50092	.80000	1.42560	.582	-2.1951	3.7951	
	50093	-1.20000	1.42560	.411	-4.1951	1.7951	
	50094	-13.60000(*)	1.42560	.000	-16.5951	-10.6049	
	50213	1.20000	1.42560	.411	-1.7951	4.1951	
	50084	7.73333(*)	1.42560	.000	4.7383	10.7284	
50090	50087	23.90000(*)	1.42560	.000	20.9049	26.8951	

	50089	22.10000(*)	1.42560	.000	19.1049	25.0951
	50091	-15.53333(*)	1.42560	.000	-18.5284	-12.5383
	50092	22.90000(*)	1.42560	.000	19.9049	25.8951
	50093	20.90000(*)	1.42560	.000	17.9049	23.8951
	50094	8.50000(*)	1.42560	.000	5.5049	11.4951
	50213	23.30000(*)	1.42560	.000	20.3049	26.2951
50091	50084	23.26667(*)	1.42560	.000	20.2716	26.2617
	50087	39.43333(*)	1.42560	.000	36.4383	42.4284
	50089	37.63333(*)	1.42560	.000	34.6383	40.6284
	50090	15.53333(*)	1.42560	.000	12.5383	18.5284
	50092	38.43333(*)	1.42560	.000	35.4383	41.4284
	50093	36.43333(*)	1.42560	.000	33.4383	39.4284
	50094	24.03333(*)	1.42560	.000	21.0383	27.0284
	50213	38.83333(*)	1.42560	.000	35.8383	41.8284
50092	50084	-15.16667(*)	1.42560	.000	-18.1617	-12.1716
	50087	1.00000	1.42560	.492	-1.9951	3.9951
	50089	-.80000	1.42560	.582	-3.7951	2.1951
	50090	-22.90000(*)	1.42560	.000	-25.8951	-19.9049
	50091	-38.43333(*)	1.42560	.000	-41.4284	-35.4383
	50093	-2.00000	1.42560	.178	-4.9951	.9951
	50094	-14.40000(*)	1.42560	.000	-17.3951	-11.4049
	50213	.40000	1.42560	.782	-2.5951	3.3951
50093	50084	-13.16667(*)	1.42560	.000	-16.1617	-10.1716
	50087	3.00000(*)	1.42560	.050	.0049	5.9951
	50089	1.20000	1.42560	.411	-1.7951	4.1951
	50090	-20.90000(*)	1.42560	.000	-23.8951	-17.9049
	50091	-36.43333(*)	1.42560	.000	-39.4284	-33.4383
	50092	2.00000	1.42560	.178	-.9951	4.9951
	50094	-12.40000(*)	1.42560	.000	-15.3951	-9.4049
	50213	2.40000	1.42560	.110	-.5951	5.3951
50094	50084	-.76667	1.42560	.597	-3.7617	2.2284
	50087	15.40000(*)	1.42560	.000	12.4049	18.3951
	50089	13.60000(*)	1.42560	.000	10.6049	16.5951
	50090	-8.50000(*)	1.42560	.000	-11.4951	-5.5049
	50091	-24.03333(*)	1.42560	.000	-27.0284	-21.0383
	50092	14.40000(*)	1.42560	.000	11.4049	17.3951
	50093	12.40000(*)	1.42560	.000	9.4049	15.3951
	50213	14.80000(*)	1.42560	.000	11.8049	17.7951
50213	50084	-15.56667(*)	1.42560	.000	-18.5617	-12.5716
	50087	.60000	1.42560	.679	-2.3951	3.5951
	50089	-1.20000	1.42560	.411	-4.1951	1.7951
	50090	-23.30000(*)	1.42560	.000	-26.2951	-20.3049
	50091	-38.83333(*)	1.42560	.000	-41.8284	-35.8383
	50092	-.40000	1.42560	.782	-3.3951	2.5951
	50093	-2.40000	1.42560	.110	-5.3951	.5951
	50094	-14.80000(*)	1.42560	.000	-17.7951	-11.8049

* The mean difference is significant at the .05 level.

Table 4: Duncan multiple range tests: Total phenolic content of mycelial extracts

Group	N	Subset for alpha = .05			
		1	2	3	4
Duncan(a) 50087	3	194.1000			
50213	3	194.7000			

50092	3	195.1000			
50089	3	195.9000			
50093	3	197.1000			
50094	3		209.5000		
50084	3		210.2667		
50090	3			218.0000	
50091	3				233.5333
Sig.		.073	.597	1.000	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 3.000.

Table 5: Descriptives: FRAP values (μmol of $\text{FeSO}_4 \cdot \text{H}_2\text{O}$ equivalents/g of extract)

Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
50084	3	28.2000	.18520	.10693	27.7399	28.6601	27.99	28.34
50087	3	22.3933	.29704	.17150	21.6554	23.1312	22.06	22.63
50089	3	26.3167	.36896	.21302	25.4001	27.2332	25.91	26.63
50090	3	27.3200	.21932	.12662	26.7752	27.8648	27.13	27.56
50091	3	12.0900	.35763	.20648	11.2016	12.9784	11.76	12.47
50092	3	12.0767	.15503	.08950	11.6916	12.4618	11.90	12.19
50093	3	11.8533	.22502	.12991	11.2944	12.4123	11.69	12.11
50094	3	20.8067	.08083	.04667	20.6059	21.0075	20.76	20.90
50213	3	13.3867	.30105	.17381	12.6388	14.1345	13.05	13.63
Total	30	22.8207	12.30379	2.24636	18.2264	27.4150	11.69	53.91

Table 6: ANOVA: FRAP values (μmol of $\text{FeSO}_4 \cdot \text{H}_2\text{O}$ equivalents/g of extract)

Group	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	1197.367	8	149.671	2221.002	.000
Within Groups	1.213	18	.067		
Total	1198.580	26			

Table 7: Multiple comparisons: FRAP values (μmol of $\text{FeSO}_4 \cdot \text{H}_2\text{O}$ equivalents/g of extract)

(I) Group	(J) Group	Mean difference (I-J)	Std. Error	Sig.	95% Confidence limit	
					Lower Bound	Upper Bound
LSD 50084	50087	5.80667(*)	.20454	.000	5.3800	6.2333
	50089	1.88333(*)	.20454	.000	1.4567	2.3100
	50090	.88000(*)	.20454	.000	.4533	1.3067
	50091	16.11000(*)	.20454	.000	15.6833	16.5367
	50092	16.12333(*)	.20454	.000	15.6967	16.5500
	50093	16.34667(*)	.20454	.000	15.9200	16.7733
	50094	7.39333(*)	.20454	.000	6.9667	7.8200
	50213	14.81333(*)	.20454	.000	14.3867	15.2400
50087	50084	-5.80667(*)	.20454	.000	-6.2333	-5.380

	50089	-3.92333(*)	.20454	.000	-4.3500	-3.4967
	50090	-4.92667(*)	.20454	.000	-5.3533	-4.5000
	50091	10.30333(*)	.20454	.000	9.8767	10.7300
	50092	10.31667(*)	.20454	.000	9.8900	10.7433
	50093	10.54000(*)	.20454	.000	10.1133	10.9667
	50094	1.58667(*)	.20454	.000	1.1600	2.0133
50089	50213	9.00667(*)	.20454	.000	8.5800	9.4333
	50084	-1.88333(*)	.20454	.000	-2.3100	-1.4567
	50087	3.92333(*)	.20454	.000	3.4967	4.3500
	50090	-1.00333(*)	.20454	.000	-1.4300	-.5767
	50091	14.22667(*)	.20454	.000	13.8000	14.6533
	50092	14.24000(*)	.20454	.000	13.8133	14.6667
	50093	14.46333(*)	.20454	.000	14.0367	14.8900
	50094	5.51000(*)	.20454	.000	5.0833	5.9367
50090	50213	12.93000(*)	.20454	.000	12.5033	13.3567
	50084	-.88000(*)	.20454	.000	-1.3067	-.4533
	50087	4.92667(*)	.20454	.000	4.5000	5.3533
	50089	1.00333(*)	.20454	.000	.5767	1.4300
	50091	15.23000(*)	.20454	.000	14.8033	15.6567
	50092	15.24333(*)	.20454	.000	14.8167	15.6700
	50093	15.46667(*)	.20454	.000	15.0400	15.8933
	50094	6.51333(*)	.20454	.000	6.0867	6.9400
50091	50213	13.93333(*)	.20454	.000	13.5067	14.3600
	50084	-16.11000(*)	.20454	.000	-16.5367	-15.6833
	50087	-10.30333(*)	.20454	.000	-10.7300	-9.8767
	50089	-14.22667(*)	.20454	.000	-14.6533	-13.8000
	50090	-15.23000(*)	.20454	.000	-15.6567	-14.8033
	50092	.01333	.20454	.949	-.4133	.4400
	50093	.23667	.20454	.261	-.1900	.6633
	50094	-8.71667(*)	.20454	.000	-9.1433	-8.2900
50092	50213	-1.29667(*)	.20454	.000	-1.7233	-.8700
	50084	-16.12333(*)	.20454	.000	-16.5500	-15.6967
	50087	-10.31667(*)	.20454	.000	-10.7433	-9.8900
	50089	-14.24000(*)	.20454	.000	-14.6667	-13.8133
	50090	-15.24333(*)	.20454	.000	-15.6700	-14.8167
	50091	-.01333	.20454	.949	-.4400	.4133
	50093	.22333	.20454	.288	-.2033	.6500
	50094	-8.73000(*)	.20454	.000	-9.1567	-8.3033
50093	50213	-1.31000(*)	.20454	.000	-1.7367	-.8833
	50084	-16.34667(*)	.20454	.000	-16.7733	-15.9200
	50087	-10.54000(*)	.20454	.000	-10.9667	-10.1133
	50089	-14.46333(*)	.20454	.000	-14.8900	-14.0367
	50090	-15.46667(*)	.20454	.000	-15.8933	-15.0400
	50091	-.23667	.20454	.261	-.6633	.1900
	50092	-.22333	.20454	.288	-.6500	.2033
	50094	-8.95333(*)	.20454	.000	-9.3800	-8.5267
50094	50213	-1.53333(*)	.20454	.000	-1.9600	-1.1067
	50084	-7.39333(*)	.20454	.000	-7.8200	-6.9667
	50087	-1.58667(*)	.20454	.000	-2.0133	-1.1600
	50089	-5.51000(*)	.20454	.000	-5.9367	-5.0833
	50090	-6.51333(*)	.20454	.000	-6.9400	-6.0867
	50091	8.71667(*)	.20454	.000	8.2900	9.1433

	50092	8.73000(*)	.20454	.000	8.3033	9.1567
	50093	8.95333(*)	.20454	.000	8.5267	9.3800
	50213	7.42000(*)	.20454	.000	6.9933	7.8467
50213	50084	-14.81333(*)	.20454	.000	-15.2400	-14.3867
	50087	-9.00667(*)	.20454	.000	-9.4333	-8.5800
	50089	-12.93000(*)	.20454	.000	-13.3567	-12.5033
	50090	-13.93333(*)	.20454	.000	-14.3600	-13.5067
	50091	1.29667(*)	.20454	.000	.8700	1.7233
	50092	1.31000(*)	.20454	.000	.8833	1.7367
	50093	1.53333(*)	.20454	.000	1.1067	1.9600
	50094	-7.42000(*)	.20454	.000	-7.8467	-6.9933

* The mean difference is significant at the .05 level.

Table 8: Duncan multiple range tests: FRAP values (μmol of $\text{FeSO}_4 \cdot \text{H}_2\text{O}$ equivalents/g of extract)

Group	N	Subset for alpha = .05						
		1	2	3	4	5	6	7
Duncan(a) 50093	3	11.8533						
50092	3	12.0767						
50091	3	12.0900						
50213	3		13.3867					
50094	3			20.8067				
50087	3				22.3933			
50089	3					26.3167		
50090	3						27.3200	
50084	3							28.2000
Sig.		.287	1.000	1.000	1.000	1.000	1.000	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 3.000.

TABLE 9: Fasting blood glucose levels of diabetic induced rats fed with mycelial extract of *P. citrinopileatus* mushroom. Table shows the mean differences between days and groups for 45 days.

Group	0 Day (mmol/L)	2 Days (mmol/L)	7 Days (mmol/L)	15 Days (mmol/L)	30 Days (mol/L)	45 Days (mmol/L)
Normal	5.08 ± 0.31 ^{aB}	5.05 ± 0.24 ^{aA}	5.20 ± 0.31 ^{aA}	5.12 ± 0.50 ^{aA}	4.88 ± 0.24 ^{aA}	4.92 ± 0.32 ^{aA}
Methanolic extract- low dose treatment	4.67 ± 0.58 ^{aAB}	14.20 ± 1.20 ^{cC}	7.88 ± 2.19 ^{bB}	7.02 ± 1.85 ^{bB}	6.67 ± 1.55 ^{bA}	6.42 ± 1.29 ^{abA}
Methanolic extract- high dose treatment	4.90 ± 0.56 ^{aB}	12.60 ± 1.68 ^{dB}	7.27 ± 1.44 ^{cB}	6.93 ± 1.21 ^{bcB}	6.23 ± 0.81 ^{abcA}	5.52 ± 0.71 ^{abA}
Drug treatment	4.63 ± 0.34 ^{aAB}	14.80 ± 1.55 ^{cC}	13.30 ± 1.53 ^{dcC}	11.93 ± 1.88 ^{cdC}	10.95 ± 2.15 ^{bcB}	9.63 ± 1.86 ^{bB}
Untreated	4.23 ± 0.34 ^{aA}	15.17 ± 1.40 ^{bC}	16.50 ± 1.70 ^{bD}	22.25 ± 1.08 ^{cD}	25.98 ± 3.59 ^{dC}	26.57 ± 3.92 ^{dC}

Values expressed are means ±SD. of 6 measurements. Means with same small letter in the same row denotes not significant ($p > 0.05$) for each group throughout 45 days. Means with same capital letter in the same column denotes not significant ($p > 0.05$) for different group in the same day.

Table 10: Descriptives: Fasting blood glucose level between groups

Day	Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
						Lower Bound	Upper Bound		
Day 0	Normal	6	5.083	.3061	.1249	4.762	5.405	4.6	5.5
	Low Dose	6	4.667	.5750	.2348	4.063	5.270	3.9	5.3
	High Dose	6	4.900	.5586	.2280	4.314	5.486	4.0	5.6
	Drug	6	4.633	.3386	.1382	4.278	4.989	4.1	5.0
	Untreated	6	4.233	.3386	.1382	3.878	4.589	3.8	4.8
	Total	30	4.703	.5014	.0915	4.516	4.891	3.8	5.6
Day 2	Normal	6	5.050	.2429	.0992	4.795	5.305	4.7	5.4
	Low Dose	6	14.200	1.2033	.4913	12.937	15.463	12.2	15.4
	High Dose	6	12.600	1.6829	.6870	10.834	14.366	10.3	14.1
	Drug	6	14.800	1.5479	.6319	13.176	16.424	11.9	16.3
	Untreated	6	15.167	1.4024	.5725	13.695	16.638	12.8	16.5
	Total	30	12.363	4.0162	.7333	10.864	13.863	4.7	16.5
Day 7	Normal	6	5.200	.3098	.1265	4.875	5.525	4.9	5.7
	Low Dose	6	7.883	2.1931	.8953	5.582	10.185	5.0	10.8
	High Dose	6	7.267	1.4418	.5886	5.754	8.780	5.4	8.9
	Drug	6	13.300	1.5323	.6256	11.692	14.908	10.6	15.0
	Untreated	6	16.500	1.6994	.6938	14.717	18.283	13.8	18.5
	Total	30	10.030	4.5100	.8234	8.346	11.714	4.9	18.5
Day 15	Normal	6	5.117	.4997	.2040	4.592	5.641	4.5	5.9
	Low Dose	6	7.017	1.8530	.7565	5.072	8.961	4.9	9.1
	High Dose	6	6.933	1.2127	.4951	5.661	8.206	5.0	8.2
	Drug	6	11.933	1.8833	.7688	9.957	13.910	9.5	14.7
	Untreated	6	22.250	1.0821	.4418	21.114	23.386	20.4	23.5
	Total	30	10.650	6.4658	1.1805	8.236	13.064	4.5	23.5
Day 30	Normal	6	4.883	.2401	.0980	4.631	5.135	4.6	5.1
	Low Dose	6	6.667	1.5539	.6344	5.036	8.297	4.8	8.9
	High Dose	6	6.233	.8116	.3313	5.382	7.085	5.3	7.4
	Drug	6	10.950	2.1548	.8797	8.689	13.211	8.3	14.0
	Untreated	6	25.983	3.5869	1.4643	22.219	29.748	23.1	32.9
	Total	30	10.943	8.1444	1.4870	7.902	13.984	4.6	32.9
Day 45	Normal	6	4.917	.3189	.1302	4.582	5.251	4.6	5.5
	Low Dose	6	6.417	1.2922	.5275	5.061	7.773	4.4	8.2
	High Dose	6	5.517	.7139	.2915	4.767	6.266	4.6	6.5
	Drug	6	9.633	1.8597	.7592	7.682	11.585	7.8	12.1
	Untreated	6	26.567	3.9226	1.6014	22.450	30.683	22.7	33.3
	Total	30	10.610	8.4989	1.5517	7.436	13.784	4.4	33.3

Table 11: ANOVA: Fasting blood glucose level

Day	Group	Sum of Squares	df	Mean Square	F	Sig.
Day 0	Between Groups	2.461	4	.615	3.186	.030
	Within Groups	4.828	25	.193		
	Total	7.290	29			
Day 2	Between Groups	424.261	4	106.065	60.945	.000
	Within Groups	43.508	25	1.740		
	Total	467.770	29			
Day 7	Between Groups	528.761	4	132.190	54.086	.000
	Within Groups	61.102	25	2.444		
	Total	589.863	29			
Day 15	Between Groups	1163.037	4	290.759	147.270	.000
	Within Groups	49.358	25	1.974		
	Total	1212.395	29			
Day 30	Between Groups	1820.395	4	455.099	110.249	.000
	Within Groups	103.198	25	4.128		
	Total	1923.594	29			
Day 45	Between Groups	1989.055	4	497.264	117.688	.000
	Within Groups	105.632	25	4.225		
	Total	2094.687	29			

Table 12: Multiple comparisons: Fasting blood glucose level between groups

Day	LSD	Dependent Variable		Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
		(I) Group	(J) Group				Lower Bound	Upper Bound
Day 0	Normal	Low Dose	High Dose	.4167	.2537	.113	-.106	.939
			Drug	.1833	.2537	.477	-.339	.706
			Untreated	.4500	.2537	.088	-.073	.973
			Untreated	.8500(*)	.2537	.003	.327	1.373
	Low Dose	Normal	High Dose	-.4167	.2537	.113	-.939	.106
			Drug	-.2333	.2537	.367	-.756	.289
			Drug	.0333	.2537	.897	-.489	.556
			Untreated	.4333	.2537	.100	-.089	.956
	High Dose	Normal	Low Dose	-.1833	.2537	.477	-.706	.339
			Low Dose	.2333	.2537	.367	-.289	.756
			Drug	.2667	.2537	.303	-.256	.789
			Untreated	.6667(*)	.2537	.014	.144	1.189
	Drug	Normal	Low Dose	-.4500	.2537	.088	-.973	.073
			Low Dose	-.0333	.2537	.897	-.556	.489
			High Dose	-.2667	.2537	.303	-.789	.256
			Untreated	.4000	.2537	.127	-.123	.923
	Untreated	Normal	Low Dose	-.8500(*)	.2537	.003	-1.373	-.327
			Low Dose	-.4333	.2537	.100	-.956	.089
			High Dose	-.6667(*)	.2537	.014	-1.189	-.144
			Drug	-.4000	.2537	.127	-.923	.123
Day 2	LSD	Normal	Low Dose	-9.1500(*)	.7617	.000	-10.719	-7.581
			High Dose	-7.5500(*)	.7617	.000	-9.119	-5.981
			Drug	-9.7500(*)	.7617	.000	-11.319	-8.181
			Untreated	-10.1167(*)	.7617	.000	-11.685	-8.548
	Low Dose	Normal	High Dose	9.1500(*)	.7617	.000	7.581	10.719

			High Dose	1.6000(*)	.7617	.046	.031	3.169
			Drug	-.6000	.7617	.438	-2.169	.969
			Untreated	-.9667	.7617	.216	-2.535	.602
		High Dose	Normal	7.5500(*)	.7617	.000	5.981	9.119
			Low Dose	-1.6000(*)	.7617	.046	-3.169	-.031
			Drug	-2.2000(*)	.7617	.008	-3.769	-.631
			Untreated	-2.5667(*)	.7617	.002	-4.135	-.998
		Drug	Normal	9.7500(*)	.7617	.000	8.181	11.319
			Low Dose	.6000	.7617	.438	-.969	2.169
			High Dose	2.2000(*)	.7617	.008	.631	3.769
			Untreated	-.3667	.7617	.634	-1.935	1.202
		Untreated	Normal	10.1167(*)	.7617	.000	8.548	11.685
			Low Dose	.9667	.7617	.216	-.602	2.535
			High Dose	2.5667(*)	.7617	.002	.998	4.135
			Drug	.3667	.7617	.634	-1.202	1.935
Day 7	LSD	Normal	Low Dose	-2.6833(*)	.9026	.006	-4.542	-.824
			High Dose	-2.0667(*)	.9026	.031	-3.926	-.208
			Drug	-8.1000(*)	.9026	.000	-9.959	-6.241
			Untreated	-11.3000(*)	.9026	.000	-13.159	-9.441
		Low Dose	Normal	2.6833(*)	.9026	.006	.824	4.542
			High Dose	.6167	.9026	.501	-1.242	2.476
			Drug	-5.4167(*)	.9026	.000	-7.276	-3.558
			Untreated	-8.6167(*)	.9026	.000	-10.476	-6.758
		High Dose	Normal	2.0667(*)	.9026	.031	.208	3.926
			Low Dose	-.6167	.9026	.501	-2.476	1.242
			Drug	-6.0333(*)	.9026	.000	-7.892	-4.174
			Untreated	-9.2333(*)	.9026	.000	-11.092	-7.374
		Drug	Normal	8.1000(*)	.9026	.000	6.241	9.959
			Low Dose	5.4167(*)	.9026	.000	3.558	7.276
			High Dose	6.0333(*)	.9026	.000	4.174	7.892
			Untreated	-3.2000(*)	.9026	.002	-5.059	-1.341
		Untreated	Normal	11.3000(*)	.9026	.000	9.441	13.159
			Low Dose	8.6167(*)	.9026	.000	6.758	10.476
			High Dose	9.2333(*)	.9026	.000	7.374	11.092
			Drug	3.2000(*)	.9026	.002	1.341	5.059
Day15	LSD	Normal	Low Dose	-1.9000(*)	.8112	.027	-3.571	-.229
			High Dose	-1.8167(*)	.8112	.034	-3.487	-.146
			Drug	-6.8167(*)	.8112	.000	-8.487	-5.146
			Untreated	-17.1333(*)	.8112	.000	-18.804	-15.463
		Low Dose	Normal	1.9000(*)	.8112	.027	.229	3.571
			High Dose	.0833	.8112	.919	-1.587	1.754
			Drug	-4.9167(*)	.8112	.000	-6.587	-3.246
			Untreated	-15.2333(*)	.8112	.000	-16.904	-13.563
		High Dose	Normal	1.8167(*)	.8112	.034	.146	3.487
			Low Dose	-.0833	.8112	.919	-1.754	1.587
			Drug	-5.0000(*)	.8112	.000	-6.671	-3.329
			Untreated	-15.3167(*)	.8112	.000	-16.987	-13.646
		Drug	Normal	6.8167(*)	.8112	.000	5.146	8.487
			Low Dose	4.9167(*)	.8112	.000	3.246	6.587
			High Dose	5.0000(*)	.8112	.000	3.329	6.671
			Untreated	-10.3167(*)	.8112	.000	-11.987	-8.646
		Untreated	Normal	17.1333(*)	.8112	.000	15.463	18.804
			Low Dose	15.2333(*)	.8112	.000	13.563	16.904
			High Dose	15.3167(*)	.8112	.000	13.646	16.987

Day30	LSD	Normal	Drug	10.3167(*)	.8112	.000	8.646	11.987			
			Low Dose	-1.7833	1.1730	.141	-4.199	.633			
			High Dose	-1.3500	1.1730	.261	-3.766	1.066			
			Drug	-6.0667(*)	1.1730	.000	-8.483	-3.651			
			Untreated	-21.1000(*)	1.1730	.000	-23.516	-18.684			
			Low Dose	Normal	1.7833	1.1730	.141	-.633	4.199		
		High Dose	.4333	1.1730	.715	-1.983	2.849				
		High Dose	Drug	-4.2833(*)	1.1730	.001	-6.699	-1.867			
			Untreated	-19.3167(*)	1.1730	.000	-21.733	-16.901			
			Normal	1.3500	1.1730	.261	-1.066	3.766			
			Low Dose	-.4333	1.1730	.715	-2.849	1.983			
			Drug	-4.7167(*)	1.1730	.000	-7.133	-2.301			
			Untreated	-19.7500(*)	1.1730	.000	-22.166	-17.334			
		Drug	Normal	6.0667(*)	1.1730	.000	3.651	8.483			
			Low Dose	4.2833(*)	1.1730	.001	1.867	6.699			
			High Dose	4.7167(*)	1.1730	.000	2.301	7.133			
			Untreated	-15.0333(*)	1.1730	.000	-17.449	-12.617			
			Untreated	Normal	21.1000(*)	1.1730	.000	18.684	23.516		
				Low Dose	19.3167(*)	1.1730	.000	16.901	21.733		
		High Dose		19.7500(*)	1.1730	.000	17.334	22.166			
		Drug		15.0333(*)	1.1730	.000	12.617	17.449			
		Day45		LSD	Normal	Low Dose	-1.5000	1.1868	.218	-3.944	.944
						High Dose	-.6000	1.1868	.618	-3.044	1.844
			Drug			-4.7167(*)	1.1868	.001	-7.161	-2.272	
Untreated	-21.6500(*)		1.1868			.000	-24.094	-19.206			
Low Dose	Normal		1.5000			1.1868	.218	-.944	3.944		
	High Dose		.9000			1.1868	.455	-1.544	3.344		
	Drug		-3.2167(*)		1.1868	.012	-5.661	-.772			
	Untreated		-20.1500(*)		1.1868	.000	-22.594	-17.706			
	High Dose		Normal		.6000	1.1868	.618	-1.844	3.044		
			Low Dose		-.9000	1.1868	.455	-3.344	1.544		
Drug			-4.1167(*)		1.1868	.002	-6.561	-1.672			
Untreated			-21.0500(*)		1.1868	.000	-23.494	-18.606			
Drug			Normal		4.7167(*)	1.1868	.001	2.272	7.161		
			Low Dose		3.2167(*)	1.1868	.012	.772	5.661		
	High Dose		4.1167(*)		1.1868	.002	1.672	6.561			
	Untreated		-16.9333(*)		1.1868	.000	-19.378	-14.489			
	Untreated		Normal		21.6500(*)	1.1868	.000	19.206	24.094		
			Low Dose		20.1500(*)	1.1868	.000	17.706	22.594		
High Dose			21.0500(*)		1.1868	.000	18.606	23.494			
Drug			16.9333(*)		1.1868	.000	14.489	19.378			

* The mean difference is significant at the .05 level.

Table 13: Duncan multiple range tests: Fasting blood glucose level between groups on day 0

Group	N	Subset for alpha = .05	
		1	2
Duncan(a) Untreated	6	4.233	
Drug	6	4.633	4.633
Low Dose	6	4.667	4.667
High Dose	6		4.900
Normal	6		5.083
Sig.		.118	.116

Means for groups in homogeneous subsets are displayed.
 a Uses Harmonic Mean Sample Size = 6.000.

Table 14: Duncan multiple range tests: Fasting blood glucose level between groups on day 2

Duncan(a)	Group	N	Subset for alpha = .05		
			1	2	3
	Normal	6	5.050		
	High Dose	6		12.600	
	Low Dose	6			14.200
	Drug	6			14.800
	Untreated	6			15.167
	Sig.		1.000	1.000	.242

Means for groups in homogeneous subsets are displayed.
 a Uses Harmonic Mean Sample Size = 6.000.

Table 15: Duncan multiple range tests: Fasting blood glucose level between groups on day 7

Duncan(a)	Group	N	Subset for alpha = .05			
			1	2	3	4
	Normal	6	5.200			
	High Dose	6		7.267		
	Low Dose	6		7.883		
	Drug	6			13.300	
	Untreated	6				16.500
	Sig.		1.000	.501	1.000	1.000

Means for groups in homogeneous subsets are displayed.
 a Uses Harmonic Mean Sample Size = 6.000.

Table 16: Duncan multiple range tests: Fasting blood glucose level between groups on day 15

Duncan(a)	Group	N	Subset for alpha = .05			
			1	2	3	4
	Normal	6	5.117			
	High Dose	6		6.933		
	Low Dose	6		7.017		
	Drug	6			11.933	
	Untreated	6				22.250
	Sig.		1.000	.919	1.000	1.000

Means for groups in homogeneous subsets are displayed.
 a Uses Harmonic Mean Sample Size = 6.000.

Table 17: Duncan multiple range tests: Fasting blood glucose level between groups on day 30

Duncan(a)	Group	N	Subset for alpha = .05		
			1	2	3
	Normal	6	4.883		
	High Dose	6	6.233		
	Low Dose	6	6.667		
	Drug	6		10.950	
	Untreated	6			25.983
	Sig.		.163	1.000	1.000

Means for groups in homogeneous subsets are displayed.
 a Uses Harmonic Mean Sample Size = 6.000.

Table 18: Duncan multiple range tests: Fasting blood glucose level between groups on day 45

Group		N	Subset for alpha = .05		
			1	2	3
Duncan(a)	Normal	6	4.917		
	High Dose	6	5.517		
	Low Dose	6	6.417		
	Drug	6		9.633	
	Untreated	6			26.567
	Sig.			.244	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 19: Descriptives: Fasting blood glucose level within group

Group	Day	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
						Lower Bound	Upper Bound		
Normal	0 Day	6	5.083	.3061	.1249	4.762	5.405	4.6	5.5
	2 Days	6	5.050	.2429	.0992	4.795	5.305	4.7	5.4
	7 Days	6	5.200	.3098	.1265	4.875	5.525	4.9	5.7
	15 Days	6	5.117	.4997	.2040	4.592	5.641	4.5	5.9
	30 Days	6	4.883	.2401	.0980	4.631	5.135	4.6	5.1
	45 Days	6	4.917	.3189	.1302	4.582	5.251	4.6	5.5
	Total	36	5.042	.3263	.0544	4.931	5.152	4.5	5.9
Low	0 Day	6	4.667	.5750	.2348	4.063	5.270	3.9	5.3
	2 Days	6	14.200	1.2033	.4913	12.937	15.463	12.2	15.4
	7 Days	6	7.883	2.1931	.8953	5.582	10.185	5.0	10.8
	15 Days	6	7.017	1.8530	.7565	5.072	8.961	4.9	9.1
	30 Days	6	6.667	1.5539	.6344	5.036	8.297	4.8	8.9
	45 Days	6	6.417	1.2922	.5275	5.061	7.773	4.4	8.2
	Total	36	7.808	3.3726	.5621	6.667	8.949	3.9	15.4
High	0 Day	6	4.900	.5586	.2280	4.314	5.486	4.0	5.6
	2 Days	6	12.600	1.6829	.6870	10.834	14.366	10.3	14.1
	7 Days	6	7.267	1.4418	.5886	5.754	8.780	5.4	8.9
	15 Days	6	6.933	1.2127	.4951	5.661	8.206	5.0	8.2
	30 Days	6	6.233	.8116	.3313	5.382	7.085	5.3	7.4
	45 Days	6	5.517	.7139	.2915	4.767	6.266	4.6	6.5
	Total	36	7.242	2.7724	.4621	6.304	8.180	4.0	14.1
Drug	0 Day	6	4.633	.3386	.1382	4.278	4.989	4.1	5.0
	2 Days	6	14.800	1.5479	.6319	13.176	16.424	11.9	16.3
	7 Days	6	13.300	1.5323	.6256	11.692	14.908	10.6	15.0
	15 Days	6	11.933	1.8833	.7688	9.957	13.910	9.5	14.7
	30 Days	6	10.950	2.1548	.8797	8.689	13.211	8.3	14.0
	45 Days	6	9.633	1.8597	.7592	7.682	11.585	7.8	12.1
	Total	36	10.875	3.6253	.6042	9.648	12.102	4.1	16.3
Untreated	0 Day	6	4.233	.3386	.1382	3.878	4.589	3.8	4.8
	2 Days	6	15.167	1.4024	.5725	13.695	16.638	12.8	16.5
	7 Days	6	16.500	1.6994	.6938	14.717	18.283	13.8	18.5
	15 Days	6	22.250	1.0821	.4418	21.114	23.386	20.4	23.5
	30 Days	6	25.983	3.5869	1.4643	22.219	29.748	23.1	32.9

45 Days	6	26.567	3.9226	1.6014	22.450	30.683	22.7	33.3
Total	36	18.450	8.0969	1.3495	15.710	21.190	3.8	33.3

Table 20: ANOVA: Fasting blood glucose level

Group		Sum of Squares	df	Mean Square	F	Sig.
Normal	Between Groups	.439	5	.088	.801	.558
	Within Groups	3.288	30	.110		
	Total	3.728	35			
Low	Between Groups	327.576	5	65.515	27.866	.000
	Within Groups	70.532	30	2.351		
	Total	398.108	35			
High	Between Groups	229.699	5	45.940	35.061	.000
	Within Groups	39.308	30	1.310		
	Total	269.008	35			
Drug	Between Groups	377.473	5	75.495	27.441	.000
	Within Groups	82.535	30	2.751		
	Total	460.008	35			
Untreated	Between Groups	2122.607	5	424.521	74.060	.000
	Within Groups	171.963	30	5.732		
	Total	2294.570	35			

Table 21: Multiple comparisons: Fasting blood glucose level within group

Dependent variable				Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
(I) Time	(J) Time		Lower Bound				Upper Bound	
Normal	LSD	0 Day	2 Days	.0333	.1911	.863	-.357	.424
			7 Days	-.1167	.1911	.546	-.507	.274
			15 Days	-.0333	.1911	.863	-.424	.357
			30 Days	.2000	.1911	.304	-.190	.590
			45 Days	.1667	.1911	.390	-.224	.557
	2 Days	0 Day	7 Days	-.0333	.1911	.863	-.424	.357
			7 Days	-.1500	.1911	.439	-.540	.240
			15 Days	-.0667	.1911	.730	-.457	.324
			30 Days	.1667	.1911	.390	-.224	.557
			45 Days	.1333	.1911	.491	-.257	.524
	7 Days	0 Day	2 Days	.1167	.1911	.546	-.274	.507
			2 Days	.1500	.1911	.439	-.240	.540
			15 Days	.0833	.1911	.666	-.307	.474
			30 Days	.3167	.1911	.108	-.074	.707
			45 Days	.2833	.1911	.149	-.107	.674
	15 Days	0 Day	2 Days	.0333	.1911	.863	-.357	.424
			2 Days	.0667	.1911	.730	-.324	.457
			7 Days	-.0833	.1911	.666	-.474	.307
			30 Days	.2333	.1911	.232	-.157	.624
			45 Days	.2000	.1911	.304	-.190	.590
	30 Days	0 Day	2 Days	-.2000	.1911	.304	-.590	.190
			2 Days	-.1667	.1911	.390	-.557	.224
			7 Days	-.3167	.1911	.108	-.707	.074
			15 Days	-.2333	.1911	.232	-.624	.157
			45 Days	-.0333	.1911	.863	-.424	.357

Low	LSD	45 Days	0 Day	-1.667	.1911	.390	-.557	.224
			2 Days	-.1333	.1911	.491	-.524	.257
			7 Days	-.2833	.1911	.149	-.674	.107
			15 Days	-.2000	.1911	.304	-.590	.190
			30 Days	.0333	.1911	.863	-.357	.424
		0 Day	2 Days	-9.5333(*)	.8853	.000	-11.341	-7.725
			7 Days	-3.2167(*)	.8853	.001	-5.025	-1.409
			15 Days	-2.3500(*)	.8853	.013	-4.158	-.542
			30 Days	-2.0000(*)	.8853	.031	-3.808	-.192
			45 Days	-1.7500	.8853	.057	-3.558	.058
		2 Days	0 Day	9.5333(*)	.8853	.000	7.725	11.341
			7 Days	6.3167(*)	.8853	.000	4.509	8.125
			15 Days	7.1833(*)	.8853	.000	5.375	8.991
			30 Days	7.5333(*)	.8853	.000	5.725	9.341
			45 Days	7.7833(*)	.8853	.000	5.975	9.591
	7 Days	0 Day	3.2167(*)	.8853	.001	1.409	5.025	
		2 Days	-6.3167(*)	.8853	.000	-8.125	-4.509	
		15 Days	.8667	.8853	.335	-.941	2.675	
		30 Days	1.2167	.8853	.180	-.591	3.025	
		45 Days	1.4667	.8853	.108	-.341	3.275	
	15 Days	0 Day	2.3500(*)	.8853	.013	.542	4.158	
		2 Days	-7.1833(*)	.8853	.000	-8.991	-5.375	
		7 Days	-.8667	.8853	.335	-2.675	.941	
		30 Days	.3500	.8853	.695	-1.458	2.158	
		45 Days	.6000	.8853	.503	-1.208	2.408	
	30 Days	0 Day	2.0000(*)	.8853	.031	.192	3.808	
		2 Days	-7.5333(*)	.8853	.000	-9.341	-5.725	
		7 Days	-1.2167	.8853	.180	-3.025	.591	
		15 Days	-.3500	.8853	.695	-2.158	1.458	
		45 Days	.2500	.8853	.780	-1.558	2.058	
45 Days	0 Day	1.7500	.8853	.057	-.058	3.558		
	2 Days	-7.7833(*)	.8853	.000	-9.591	-5.975		
	7 Days	-1.4667	.8853	.108	-3.275	.341		
	15 Days	-.6000	.8853	.503	-2.408	1.208		
	30 Days	-.2500	.8853	.780	-2.058	1.558		
High	LSD	0 Day	2 Days	-7.7000(*)	.6609	.000	-9.050	-6.350
			7 Days	-2.3667(*)	.6609	.001	-3.716	-1.017
			15 Days	-2.0333(*)	.6609	.004	-3.383	-.684
			30 Days	-1.3333	.6609	.053	-2.683	.016
			45 Days	-.6167	.6609	.358	-1.966	.733
		2 Days	0 Day	7.7000(*)	.6609	.000	6.350	9.050
			7 Days	5.3333(*)	.6609	.000	3.984	6.683
			15 Days	5.6667(*)	.6609	.000	4.317	7.016
			30 Days	6.3667(*)	.6609	.000	5.017	7.716
			45 Days	7.0833(*)	.6609	.000	5.734	8.433
		7 Days	0 Day	2.3667(*)	.6609	.001	1.017	3.716
			2 Days	-5.3333(*)	.6609	.000	-6.683	-3.984
			15 Days	.3333	.6609	.618	-1.016	1.683
			30 Days	1.0333	.6609	.128	-.316	2.383
			45 Days	1.7500(*)	.6609	.013	.400	3.100
	15 Days	0 Day	2.0333(*)	.6609	.004	.684	3.383	
		2 Days	-5.6667(*)	.6609	.000	-7.016	-4.317	
		7 Days	-.3333	.6609	.618	-1.683	1.016	
		30 Days	.7000	.6609	.298	-.650	2.050	

Drug	LSD	30 Days	45 Days	1.4167(*)	.6609	.040	.067	2.766		
			0 Day	1.3333	.6609	.053	-.016	2.683		
			2 Days	-6.3667(*)	.6609	.000	-7.716	-5.017		
			7 Days	-1.0333	.6609	.128	-2.383	.316		
			15 Days	-.7000	.6609	.298	-2.050	.650		
		45 Days	45 Days	.7167	.6609	.287	-.633	2.066		
			0 Day	.6167	.6609	.358	-.733	1.966		
			2 Days	-7.0833(*)	.6609	.000	-8.433	-5.734		
			7 Days	-1.7500(*)	.6609	.013	-3.100	-.400		
			15 Days	-1.4167(*)	.6609	.040	-2.766	-.067		
		0 Day	30 Days	-.7167	.6609	.287	-2.066	.633		
			2 Days	-10.1667(*)	.9576	.000	-12.122	-8.211		
			7 Days	-8.6667(*)	.9576	.000	-10.622	-6.711		
			15 Days	-7.3000(*)	.9576	.000	-9.256	-5.344		
			30 Days	-6.3167(*)	.9576	.000	-8.272	-4.361		
		2 Days	45 Days	-5.0000(*)	.9576	.000	-6.956	-3.044		
			0 Day	10.1667(*)	.9576	.000	8.211	12.122		
			7 Days	1.5000	.9576	.128	-.456	3.456		
			15 Days	2.8667(*)	.9576	.005	.911	4.822		
			30 Days	3.8500(*)	.9576	.000	1.894	5.806		
		7 Days	45 Days	5.1667(*)	.9576	.000	3.211	7.122		
			0 Day	8.6667(*)	.9576	.000	6.711	10.622		
			2 Days	-1.5000	.9576	.128	-3.456	.456		
			15 Days	1.3667	.9576	.164	-.589	3.322		
			30 Days	2.3500(*)	.9576	.020	.394	4.306		
		15 Days	45 Days	3.6667(*)	.9576	.001	1.711	5.622		
			0 Day	7.3000(*)	.9576	.000	5.344	9.256		
			2 Days	-2.8667(*)	.9576	.005	-4.822	-.911		
			7 Days	-1.3667	.9576	.164	-3.322	.589		
			30 Days	.9833	.9576	.313	-.972	2.939		
		30 Days	45 Days	2.3000(*)	.9576	.023	.344	4.256		
			0 Day	6.3167(*)	.9576	.000	4.361	8.272		
			2 Days	-3.8500(*)	.9576	.000	-5.806	-1.894		
			7 Days	-2.3500(*)	.9576	.020	-4.306	-.394		
			15 Days	-.9833	.9576	.313	-2.939	.972		
		45 Days	45 Days	1.3167	.9576	.179	-.639	3.272		
			0 Day	5.0000(*)	.9576	.000	3.044	6.956		
			2 Days	-5.1667(*)	.9576	.000	-7.122	-3.211		
			7 Days	-3.6667(*)	.9576	.001	-5.622	-1.711		
			15 Days	-2.3000(*)	.9576	.023	-4.256	-.344		
		Untreated	LSD	0 Day	30 Days	-1.3167	.9576	.179	-3.272	.639
					2 Days	-10.9333(*)	1.3823	.000	-13.756	-8.110
					7 Days	-12.2667(*)	1.3823	.000	-15.090	-9.444
					15 Days	-18.0167(*)	1.3823	.000	-20.840	-15.194
					30 Days	-21.7500(*)	1.3823	.000	-24.573	-18.927
2 Days	45 Days			-22.3333(*)	1.3823	.000	-25.156	-19.510		
	0 Day			10.9333(*)	1.3823	.000	8.110	13.756		
	7 Days			-1.3333	1.3823	.342	-4.156	1.490		
	15 Days			-7.0833(*)	1.3823	.000	-9.906	-4.260		
	30 Days			-10.8167(*)	1.3823	.000	-13.640	-7.994		
7 Days	45 Days			-11.4000(*)	1.3823	.000	-14.223	-8.577		
	0 Day			12.2667(*)	1.3823	.000	9.444	15.090		
	2 Days			1.3333	1.3823	.342	-1.490	4.156		
	15 Days			-5.7500(*)	1.3823	.000	-8.573	-2.927		

	30 Days	-9.4833(*)	1.3823	.000	-12.306	-6.660
	45 Days	-10.0667(*)	1.3823	.000	-12.890	-7.244
15 Days	0 Day	18.0167(*)	1.3823	.000	15.194	20.840
	2 Days	7.0833(*)	1.3823	.000	4.260	9.906
	7 Days	5.7500(*)	1.3823	.000	2.927	8.573
	30 Days	-3.7333(*)	1.3823	.011	-6.556	-.910
	45 Days	-4.3167(*)	1.3823	.004	-7.140	-1.494
30 Days	0 Day	21.7500(*)	1.3823	.000	18.927	24.573
	2 Days	10.8167(*)	1.3823	.000	7.994	13.640
	7 Days	9.4833(*)	1.3823	.000	6.660	12.306
	15 Days	3.7333(*)	1.3823	.011	.910	6.556
	45 Days	-.5833	1.3823	.676	-3.406	2.240
45 Days	0 Day	22.3333(*)	1.3823	.000	19.510	25.156
	2 Days	11.4000(*)	1.3823	.000	8.577	14.223
	7 Days	10.0667(*)	1.3823	.000	7.244	12.890
	15 Days	4.3167(*)	1.3823	.004	1.494	7.140
	30 Days	.5833	1.3823	.676	-2.240	3.406

* The mean difference is significant at the .05 level.

Table 22: Duncan multiple range tests: Fasting blood glucose level within normal group

Duncan(a)	Time	N	Subset for alpha = .05	
			1	
	30 Days	6	4.883	
	45 Days	6	4.917	
	2 Days	6	5.050	
	0 Day	6	5.083	
	15 Days	6	5.117	
	7 Days	6	5.200	
	Sig.		.155	

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000

Table 23: Duncan multiple range tests: Fasting blood glucose level within low dose treated diabetic group

Duncan(a)	Time	N	Subset for alpha = .05		
			1	2	3
	0 Day	6	4.667		
	45 Days	6	6.417	6.417	
	30 Days	6		6.667	
	15 Days	6		7.017	
	7 Days	6		7.883	
	2 Days	6			14.200
	Sig.		.057	.140	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.

Table 24: Duncan multiple range tests: Fasting blood glucose level within high dose treated diabetic group

Duncan(a)	Time	N	Subset for alpha = .05			
			1	2	3	4
	0 Day	6	4.900			
	45 Days	6	5.517	5.517		

30 Days	6	6.233	6.233	6.233	
15 Days	6		6.933	6.933	
7 Days	6			7.267	
2 Days	6				12.600
Sig.		.065	.050	.150	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 25: Duncan multiple range tests: Fasting blood glucose level within drug treated diabetic group

Time	N	Subset for alpha = .05				
		1	2	3	4	5
Duncan(a) 0 Day	6	4.633				
45 Days	6		9.633			
30 Days	6		10.950	10.950		
15 Days	6			11.933	11.933	
7 Days	6				13.300	13.300
2 Days	6					14.800
Sig.		1.000	.179	.313	.164	.128

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 26: Duncan multiple range tests: Fasting blood glucose level within untreated diabetic group

Time	N	Subset for alpha = .05			
		1	2	3	4
Duncan(a) 0 Day	6	4.233			
2 Days	6		15.167		
7 Days	6		16.500		
15 Days	6			22.250	
30 Days	6				25.983
45 Days	6				26.567
Sig.		1.000	.342	1.000	.676

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

TABLE 27: Fasting body weights of diabetic induced rats fed with mycelial extract of *P. citrinopileatus* mushroom.
Table shows the mean differences between days for each group for 45 days.

Group	0 Hour (grams)	2 Days (grams)	7 Days (grams)	15 Days (grams)	30 Days (grams)	45 Days (grams)
Normal	258.33 ± 9.83 ^{aB}	258.33 ± 9.83 ^{aB}	279.17 ± 18.82 ^{abC}	287.50 ± 20.92 ^{bB}	314.17 ± 20.10 ^{cC}	326.67 ± 20.41 ^{dD}
Methanolic extract-low dose treatment	237.50 ± 13.69 ^{aA}	237.50 ± 13.69 ^{aA}	241.67 ± 25.82 ^{aAB}	233.33 ± 20.41 ^{aA}	250.00 ± 31.62 ^{aB}	254.17 ± 29.23 ^{aB}
Methanolic extract-high dose treatment	254.17 ± 10.21 ^{aAB}	254.17 ± 10.21 ^{aAB}	254.17 ± 10.21 ^{aB}	245.83 ± 18.82 ^{aA}	275.00 ± 22.36 ^{bB}	287.50 ± 13.69 ^{bC}
Drug treatment	250.00 ± 15.81 ^{bAB}	250.00 ± 15.81 ^{bAB}	229.17 ± 18.82 ^{abA}	229.17 ± 18.82 ^{abA}	216.67 ± 25.82 ^{aA}	241.67 ± 20.41 ^{bB}
Untreated	320.83 ± 24.58 ^{dC}	320.83 ± 24.58 ^{dC}	283.33 ± 20.41 ^{cC}	225.00 ± 27.39 ^{bA}	208.33 ± 12.91 ^{abA}	195.83 ± 24.58 ^{aA}

Values expressed are means ±SD. of 6 measurements. Means with same small letter in the same row denotes not significant ($p > 0.05$) for each group throughout 45 days. Means with same capital letter in the same column denotes not significant ($p > 0.05$) for different group in the same day.

Table 28: Descriptives: Fasting body weights between groups

Day	Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
						Lower Bound	Upper Bound		
Day 0	Normal	6	258.333	9.8319	4.0139	248.015	268.651	250.0	270.0
	Low Dose	6	237.500	13.6931	5.5902	223.130	251.870	225.0	250.0
	High Dose	6	254.167	10.2062	4.1667	243.456	264.877	250.0	275.0
	Drug	6	250.000	15.8114	6.4550	233.407	266.593	225.0	275.0
	Untreated	6	320.833	24.5798	10.0347	295.038	346.628	300.0	350.0
	Total	30	264.167	33.0904	6.0414	251.811	276.523	225.0	350.0
Day 2	Normal	6	258.333	9.8319	4.0139	248.015	268.651	250.0	270.0
	Low Dose	6	237.500	13.6931	5.5902	223.130	251.870	225.0	250.0
	High Dose	6	254.167	10.2062	4.1667	243.456	264.877	250.0	275.0
	Drug	6	250.000	15.8114	6.4550	233.407	266.593	225.0	275.0
	Untreated	6	320.833	24.5798	10.0347	295.038	346.628	300.0	350.0
	Total	30	264.167	33.0904	6.0414	251.811	276.523	225.0	350.0
Day 7	Normal	6	279.167	18.8193	7.6830	259.417	298.916	250.0	300.0
	Low Dose	6	241.667	25.8199	10.5409	214.570	268.763	200.0	275.0
	High Dose	6	254.167	10.2062	4.1667	243.456	264.877	250.0	275.0
	Drug	6	229.167	18.8193	7.6830	209.417	248.916	200.0	250.0
	Untreated	6	283.333	20.4124	8.3333	261.912	304.755	250.0	300.0
	Total	30	257.500	27.9701	5.1066	247.056	267.944	200.0	300.0
Day 15	Normal	6	287.500	20.9165	8.5391	265.549	309.451	250.0	300.0
	Low Dose	6	233.333	20.4124	8.3333	211.912	254.755	200.0	250.0
	High Dose	6	245.833	18.8193	7.6830	226.084	265.583	225.0	275.0
	Drug	6	229.167	18.8193	7.6830	209.417	248.916	200.0	250.0
	Untreated	6	225.000	27.3861	11.1803	196.260	253.740	200.0	250.0
	Total	30	244.167	30.5717	5.5816	232.751	255.582	200.0	300.0
Day 30	Normal	6	314.167	20.1039	8.2074	293.069	335.264	300.0	350.0
	Low Dose	6	250.000	31.6228	12.9099	216.814	283.186	200.0	275.0
	High Dose	6	275.000	22.3607	9.1287	251.534	298.466	250.0	300.0
	Drug	6	216.667	25.8199	10.5409	189.570	243.763	200.0	250.0
	Untreated	6	208.333	12.9099	5.2705	194.785	221.881	200.0	225.0
	Total	30	252.833	45.0992	8.2339	235.993	269.674	200.0	350.0
Day 45	Normal	6	326.667	20.4124	8.3333	305.245	348.088	300.0	350.0
	Low Dose	6	254.167	29.2261	11.9315	223.496	284.838	200.0	275.0
	High Dose	6	287.500	13.6931	5.5902	273.130	301.870	275.0	300.0
	Drug	6	241.667	20.4124	8.3333	220.245	263.088	200.0	250.0
	Untreated	6	195.833	24.5798	10.0347	170.038	221.628	175.0	225.0
	Total	30	261.167	49.3000	9.0009	242.758	279.576	175.0	350.0

Table 29: ANOVA: Fasting body weights

Day	Group	Sum of Squares	df	Mean Square	F	Sig.
Day 0	Between Groups	25541.667	4	6385.417	25.696	.000
	Within Groups	6212.500	25	248.500		
	Total	31754.167	29			
Day 2	Between Groups	25541.667	4	6385.417	25.696	.000
	Within Groups	6212.500	25	248.500		
	Total	31754.167	29			
Day 7	Between Groups	13208.333	4	3302.083	8.709	.000
	Within Groups	9479.167	25	379.167		

	Total	22687.500	29			
Day 15	Between Groups	15541.667	4	3885.417	8.401	.000
	Within Groups	11562.500	25	462.500		
	Total	27104.167	29			
Day 30	Between Groups	45296.667	4	11324.167	20.683	.000
	Within Groups	13687.500	25	547.500		
	Total	58984.167	29			
Day 45	Between Groups	58088.333	4	14522.083	29.288	.000
	Within Groups	12395.833	25	495.833		
	Total	70484.167	29			

Table 30: Multiple comparisons: Fasting body weights between groups

Dependent Variable				Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
(I) Group	(J) Group		Lower Bound				Upper Bound	
Day 0	LSD	Normal	Low Dose	20.8333(*)	9.1013	.031	2.089	39.578
			High Dose	4.1667	9.1013	.651	-14.578	22.911
			Drug	8.3333	9.1013	.369	-10.411	27.078
			Untreated	-62.5000(*)	9.1013	.000	-81.244	-43.756
	Low Dose	Normal	High Dose	-20.8333(*)	9.1013	.031	-39.578	-2.089
			Drug	-16.6667	9.1013	.079	-35.411	2.078
			Untreated	-12.5000	9.1013	.182	-31.244	6.244
			Untreated	-83.3333(*)	9.1013	.000	-102.078	-64.589
	High Dose	Normal	Low Dose	-4.1667	9.1013	.651	-22.911	14.578
			Drug	16.6667	9.1013	.079	-2.078	35.411
			Untreated	4.1667	9.1013	.651	-14.578	22.911
			Untreated	-66.6667(*)	9.1013	.000	-85.411	-47.922
	Drug	Normal	Low Dose	-8.3333	9.1013	.369	-27.078	10.411
			High Dose	12.5000	9.1013	.182	-6.244	31.244
			Untreated	-4.1667	9.1013	.651	-22.911	14.578
			Untreated	-70.8333(*)	9.1013	.000	-89.578	-52.089
	Untreated	Normal	Low Dose	62.5000(*)	9.1013	.000	43.756	81.244
			High Dose	83.3333(*)	9.1013	.000	64.589	102.078
			Drug	66.6667(*)	9.1013	.000	47.922	85.411
			Drug	70.8333(*)	9.1013	.000	52.089	89.578
Day 2	LSD	Normal	Low Dose	20.8333(*)	9.1013	.031	2.089	39.578
			High Dose	4.1667	9.1013	.651	-14.578	22.911
			Drug	8.3333	9.1013	.369	-10.411	27.078
			Untreated	-62.5000(*)	9.1013	.000	-81.244	-43.756
	Low Dose	Normal	High Dose	-20.8333(*)	9.1013	.031	-39.578	-2.089
			Drug	-16.6667	9.1013	.079	-35.411	2.078
			Untreated	-12.5000	9.1013	.182	-31.244	6.244
			Untreated	-83.3333(*)	9.1013	.000	-102.078	-64.589
	High Dose	Normal	Low Dose	-4.1667	9.1013	.651	-22.911	14.578
			Drug	16.6667	9.1013	.079	-2.078	35.411
			Untreated	4.1667	9.1013	.651	-14.578	22.911
			Untreated	-66.6667(*)	9.1013	.000	-85.411	-47.922
	Drug	Normal	Low Dose	-8.3333	9.1013	.369	-27.078	10.411
			High Dose	12.5000	9.1013	.182	-6.244	31.244
			Untreated	-4.1667	9.1013	.651	-22.911	14.578
			Untreated	-70.8333(*)	9.1013	.000	-89.578	-52.089
	Untreated	Normal	Low Dose	62.5000(*)	9.1013	.000	43.756	81.244
			High Dose	83.3333(*)	9.1013	.000	64.589	102.078

Day 7	LSD	Normal	High Dose	66.6667(*)	9.1013	.000	47.922	85.411		
			Drug	70.8333(*)	9.1013	.000	52.089	89.578		
			Low Dose	37.5000(*)	11.2423	.003	14.346	60.654		
			High Dose	25.0000(*)	11.2423	.035	1.846	48.154		
			Drug	50.0000(*)	11.2423	.000	26.846	73.154		
			Untreated	-4.1667	11.2423	.714	-27.321	18.987		
		Low Dose	Normal	-37.5000(*)	11.2423	.003	-60.654	-14.346		
			High Dose	-12.5000	11.2423	.277	-35.654	10.654		
			Drug	12.5000	11.2423	.277	-10.654	35.654		
			Untreated	-41.6667(*)	11.2423	.001	-64.821	-18.513		
			High Dose	Normal	-25.0000(*)	11.2423	.035	-48.154	-1.846	
			Low Dose	12.5000	11.2423	.277	-10.654	35.654		
		Drug	Drug	25.0000(*)	11.2423	.035	1.846	48.154		
			Untreated	-29.1667(*)	11.2423	.016	-52.321	-6.013		
			Normal	-50.0000(*)	11.2423	.000	-73.154	-26.846		
			Low Dose	-12.5000	11.2423	.277	-35.654	10.654		
			High Dose	-25.0000(*)	11.2423	.035	-48.154	-1.846		
			Untreated	-54.1667(*)	11.2423	.000	-77.321	-31.013		
		Untreated	Normal	4.1667	11.2423	.714	-18.987	27.321		
			Low Dose	41.6667(*)	11.2423	.001	18.513	64.821		
			High Dose	29.1667(*)	11.2423	.016	6.013	52.321		
Drug	54.1667(*)		11.2423	.000	31.013	77.321				
Low Dose	54.1667(*)		12.4164	.000	28.595	79.739				
High Dose	41.6667(*)		12.4164	.003	16.095	67.239				
Day 15	LSD	Normal	Drug	58.3333(*)	12.4164	.000	32.761	83.905		
			Untreated	62.5000(*)	12.4164	.000	36.928	88.072		
			Low Dose	Normal	-54.1667(*)	12.4164	.000	-79.739	-28.595	
			High Dose	-12.5000	12.4164	.324	-38.072	13.072		
			Drug	4.1667	12.4164	.740	-21.405	29.739		
			Untreated	8.3333	12.4164	.508	-17.239	33.905		
		High Dose	Normal	-41.6667(*)	12.4164	.003	-67.239	-16.095		
			Low Dose	12.5000	12.4164	.324	-13.072	38.072		
			Drug	16.6667	12.4164	.192	-8.905	42.239		
			Untreated	20.8333	12.4164	.106	-4.739	46.405		
			Drug	Normal	-58.3333(*)	12.4164	.000	-83.905	-32.761	
			Low Dose	-4.1667	12.4164	.740	-29.739	21.405		
		Drug	High Dose	-16.6667	12.4164	.192	-42.239	8.905		
			Untreated	4.1667	12.4164	.740	-21.405	29.739		
			Normal	-62.5000(*)	12.4164	.000	-88.072	-36.928		
			Low Dose	-8.3333	12.4164	.508	-33.905	17.239		
			High Dose	-20.8333	12.4164	.106	-46.405	4.739		
			Drug	-4.1667	12.4164	.740	-29.739	21.405		
		Day 30	LSD	Normal	Low Dose	64.1667(*)	13.5093	.000	36.344	91.990
					High Dose	39.1667(*)	13.5093	.008	11.344	66.990
					Drug	97.5000(*)	13.5093	.000	69.677	125.323
Untreated	105.8333(*)				13.5093	.000	78.010	133.656		
Low Dose	Normal			-64.1667(*)	13.5093	.000	-91.990	-36.344		
	High Dose			-25.0000	13.5093	.076	-52.823	2.823		
	Drug			33.3333(*)	13.5093	.021	5.510	61.156		
	Untreated			41.6667(*)	13.5093	.005	13.844	69.490		
High Dose	Normal			-39.1667(*)	13.5093	.008	-66.990	-11.344		
	Low Dose			25.0000	13.5093	.076	-2.823	52.823		
	Drug			58.3333(*)	13.5093	.000	30.510	86.156		
	Untreated			66.6667(*)	13.5093	.000	38.844	94.490		

Day 45	LSD	Drug	Normal	-97.5000(*)	13.5093	.000	-125.323	-69.677
			Low Dose	-33.3333(*)	13.5093	.021	-61.156	-5.510
			High Dose	-58.3333(*)	13.5093	.000	-86.156	-30.510
			Untreated	8.3333	13.5093	.543	-19.490	36.156
		Untreated	Normal	-105.8333(*)	13.5093	.000	-133.656	-78.010
			Low Dose	-41.6667(*)	13.5093	.005	-69.490	-13.844
			High Dose	-66.6667(*)	13.5093	.000	-94.490	-38.844
			Drug	-8.3333	13.5093	.543	-36.156	19.490
		Normal	Low Dose	72.5000(*)	12.8560	.000	46.022	98.978
			High Dose	39.1667(*)	12.8560	.005	12.689	65.644
			Drug	85.0000(*)	12.8560	.000	58.522	111.478
			Untreated	130.8333(*)	12.8560	.000	104.356	157.311
	Low Dose	Normal	-72.5000(*)	12.8560	.000	-98.978	-46.022	
		High Dose	-33.3333(*)	12.8560	.016	-59.811	-6.856	
		Drug	12.5000	12.8560	.340	-13.978	38.978	
		Untreated	58.3333(*)	12.8560	.000	31.856	84.811	
	High Dose	Normal	-39.1667(*)	12.8560	.005	-65.644	-12.689	
		Low Dose	33.3333(*)	12.8560	.016	6.856	59.811	
		Drug	45.8333(*)	12.8560	.001	19.356	72.311	
		Untreated	91.6667(*)	12.8560	.000	65.189	118.144	
	Drug	Normal	-85.0000(*)	12.8560	.000	-111.478	-58.522	
		Low Dose	-12.5000	12.8560	.340	-38.978	13.978	
		High Dose	-45.8333(*)	12.8560	.001	-72.311	-19.356	
		Untreated	45.8333(*)	12.8560	.001	19.356	72.311	
Untreated	Normal	-130.8333(*)	12.8560	.000	-157.311	-104.356		
	Low Dose	-58.3333(*)	12.8560	.000	-84.811	-31.856		
	High Dose	-91.6667(*)	12.8560	.000	-118.144	-65.189		
	Drug	-45.8333(*)	12.8560	.001	-72.311	-19.356		

* The mean difference is significant at the .05 level.

Table 31: Duncan multiple range tests: Fasting body weights between groups on day 0

Group	N	Subset for alpha = .05		
		1	2	3
Duncan(a) Low Dose	6	237.500		
Drug	6	250.000	250.000	
High Dose	6	254.167	254.167	
Normal	6		258.333	
Untreated	6			320.833
Sig.		.095	.396	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 32: Duncan multiple range tests: Fasting body weights between groups on day 2

Group	N	Subset for alpha = .05		
		1	2	3
Duncan(a) Low Dose	6	237.500		
Drug	6	250.000	250.000	
High Dose	6	254.167	254.167	
Normal	6		258.333	
Untreated	6			320.833

Sig.		.095	.396	1.000
------	--	------	------	-------

Means for groups in homogeneous subsets are displayed.
a Uses Harmonic Mean Sample Size = 6.000.

Table 33: Duncan multiple range tests: Fasting body weights between groups on day 7

Duncan(a)	Group	N	Subset for alpha = .05		
			1	2	3
	Drug	6	229.167		
	Low Dose	6	241.667	241.667	
	High Dose	6		254.167	
	Normal	6			279.167
	Untreated	6			283.333
	Sig.		.277	.277	.714

Means for groups in homogeneous subsets are displayed.
a Uses Harmonic Mean Sample Size = 6.000.

Table 34: Duncan multiple range tests: Fasting body weights between groups on day 15

Duncan(a)	Group	N	Subset for alpha = .05	
			1	2
	Untreated	6	225.000	
	Drug	6	229.167	
	Low Dose	6	233.333	
	High Dose	6	245.833	
	Normal	6		287.500
	Sig.		.136	1.000

Means for groups in homogeneous subsets are displayed.
a Uses Harmonic Mean Sample Size = 6.000.

Table 35: Duncan multiple range tests: Fasting body weights between groups on day 30

Duncan(a)	Group	N	Subset for alpha = .05		
			1	2	3
	Untreated	6	208.333		
	Drug	6	216.667		
	Low Dose	6		250.000	
	High Dose	6		275.000	
	Normal	6			314.167
	Sig.		.543	.076	1.000

Means for groups in homogeneous subsets are displayed.
a Uses Harmonic Mean Sample Size = 6.000.

Table 36: Duncan multiple range tests: Fasting body weights between groups on day 45

Group		N	Subset for alpha = .05			
			1	2	3	4
Duncan(a)	Untreated	6	195.833	241.667	287.500	326.667
	Drug	6				
	Low Dose	6	254.167			
	High Dose	6				
	Normal	6				
	Sig.	6	1.000	.340	1.000	

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 37: Descriptives: Fasting body weights within group

Group	Day	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
						Lower Bound	Upper Bound		
Normal	0 Day	6	258.3333	9.83192	4.01386	248.0154	268.6513	250.00	270.00
	2 Days	6	258.3333	9.83192	4.01386	248.0154	268.6513	250.00	270.00
	7 Days	6	279.1667	18.81932	7.68295	259.4170	298.9163	250.00	300.00
	15 Days	6	287.5000	20.91650	8.53913	265.5495	309.4505	250.00	300.00
	30 Days	6	314.1667	20.10390	8.20738	293.0689	335.2644	300.00	350.00
	45 Days	6	326.6667	20.41241	8.33333	305.2452	348.0882	300.00	350.00
	Total	36	287.3611	30.76376	5.12729	276.9522	297.7701	250.00	350.00
Low Dose	0 Day	6	237.5000	13.69306	5.59017	223.1300	251.8700	225.00	250.00
	2 Days	6	237.5000	13.69306	5.59017	223.1300	251.8700	225.00	250.00
	7 Days	6	241.6667	25.81989	10.54093	214.5704	268.7630	200.00	275.00
	15 Days	6	233.3333	20.41241	8.33333	211.9118	254.7548	200.00	250.00
	30 Days	6	250.0000	31.62278	12.90994	216.8139	283.1861	200.00	275.00
	45 Days	6	254.1667	29.22613	11.93152	223.4957	284.8376	200.00	275.00
	Total	36	242.3611	23.00578	3.83430	234.5771	250.1451	200.00	275.00
High Dose	0 Day	6	254.1667	10.20621	4.16667	243.4559	264.8774	250.00	275.00
	2 Days	6	254.1667	10.20621	4.16667	243.4559	264.8774	250.00	275.00
	7 Days	6	254.1667	10.20621	4.16667	243.4559	264.8774	250.00	275.00
	15 Days	6	245.8333	18.81932	7.68295	226.0837	265.5830	225.00	275.00
	30 Days	6	275.0000	22.36068	9.12871	251.5339	298.4661	250.00	300.00
	45 Days	6	287.5000	13.69306	5.59017	273.1300	301.8700	275.00	300.00
	Total	36	261.8056	20.25385	3.37564	254.9526	268.6585	225.00	300.00
Drug	0 Day	6	250.0000	15.81139	6.45497	233.4070	266.5930	225.00	275.00
	2 Days	6	250.0000	15.81139	6.45497	233.4070	266.5930	225.00	275.00
	7 Days	6	229.1667	18.81932	7.68295	209.4170	248.9163	200.00	250.00
	15 Days	6	229.1667	18.81932	7.68295	209.4170	248.9163	200.00	250.00
	30 Days	6	216.6667	25.81989	10.54093	189.5704	243.7630	200.00	250.00
	45 Days	6	241.6667	20.41241	8.33333	220.2452	263.0882	200.00	250.00
	Total	36	236.1111	21.91252	3.65209	228.6970	243.5252	200.00	275.00
Untreated	0 Day	6	320.8333	24.57980	10.03466	295.0384	346.6283	300.00	350.00
	2 Days	6	320.8333	24.57980	10.03466	295.0384	346.6283	300.00	350.00
	7 Days	6	283.3333	20.41241	8.33333	261.9118	304.7548	250.00	300.00
	15 Days	6	225.0000	27.38613	11.18034	196.2600	253.7400	200.00	250.00
	30 Days	6	208.3333	12.90994	5.27046	194.7852	221.8815	200.00	225.00
	45 Days	6	195.8333	24.57980	10.03466	170.0384	221.6283	175.00	225.00
	Total	36	259.0278	56.42719	9.40453	239.9356	278.1200	175.00	350.00

Table 38: ANOVA: Fasting body weights

Group		Sum of Squares	df	Mean Square	F	Sig.
Normal	Between Groups	24095.139	5	4819.028	16.012	.000
	Within Groups	9029.167	30	300.972		
	Total	33124.306	35			
Low Dose	Between Groups	1961.806	5	392.361	.711	.620
	Within Groups	16562.500	30	552.083		
	Total	18524.306	35			
High Dose	Between Groups	7586.806	5	1517.361	6.723	.000
	Within Groups	6770.833	30	225.694		
	Total	14357.639	35			
Drug	Between Groups	5347.222	5	1069.444	2.800	.034
	Within Groups	11458.333	30	381.944		
	Total	16805.556	35			
Untreated	Between Groups	95711.806	5	19142.361	36.510	.000
	Within Groups	15729.167	30	524.306		
	Total	111440.972	35			

Table 39: Multiple comparisons: Fasting body weights within group

Dependent Variable	(I) Time	(J) Time	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval		
						Lower Bound	Upper Bound	
Normal	LSD	0 Day	2 Days	.00000	10.01619	1.000	-20.4558	20.4558
			7 Days	-20.83333(*)	10.01619	.046	-41.2891	-.3775
			15 Days	-29.16667(*)	10.01619	.007	-49.6225	-8.7109
			30 Days	-55.83333(*)	10.01619	.000	-76.2891	-35.3775
			45 Days	-68.33333(*)	10.01619	.000	-88.7891	-47.8775
	2 Days	0 Day	7 Days	-20.83333(*)	10.01619	.046	-41.2891	-.3775
			15 Days	-29.16667(*)	10.01619	.007	-49.6225	-8.7109
			30 Days	-55.83333(*)	10.01619	.000	-76.2891	-35.3775
			45 Days	-68.33333(*)	10.01619	.000	-88.7891	-47.8775
			7 Days	20.83333(*)	10.01619	.046	.3775	41.2891
	7 Days	0 Day	2 Days	20.83333(*)	10.01619	.046	.3775	41.2891
			15 Days	-8.33333	10.01619	.412	-28.7891	12.1225
			30 Days	-35.00000(*)	10.01619	.001	-55.4558	-14.5442
			45 Days	-47.50000(*)	10.01619	.000	-67.9558	-27.0442
			15 Days	29.16667(*)	10.01619	.007	8.7109	49.6225
	15 Days	0 Day	2 Days	29.16667(*)	10.01619	.007	8.7109	49.6225
			7 Days	8.33333	10.01619	.412	-12.1225	28.7891
			30 Days	-26.66667(*)	10.01619	.012	-47.1225	-6.2109
			45 Days	-39.16667(*)	10.01619	.000	-59.6225	-18.7109
			30 Days	55.83333(*)	10.01619	.000	35.3775	76.2891
	30 Days	0 Day	2 Days	55.83333(*)	10.01619	.000	35.3775	76.2891
			7 Days	35.00000(*)	10.01619	.001	14.5442	55.4558
			15 Days	26.66667(*)	10.01619	.012	6.2109	47.1225
			45 Days	-12.50000	10.01619	.222	-32.9558	7.9558
			45 Days	68.33333(*)	10.01619	.000	47.8775	88.7891
	45 Days	0 Day	2 Days	68.33333(*)	10.01619	.000	47.8775	88.7891
			7 Days	47.50000(*)	10.01619	.000	27.0442	67.9558

Low Dose	LSD	0 Day	15 Days	39.16667(*)	10.01619	.000	18.7109	59.6225	
			30 Days	12.50000	10.01619	.222	-7.9558	32.9558	
			2 Days	.00000	13.56568	1.000	-27.7048	27.7048	
			7 Days	-4.16667	13.56568	.761	-31.8715	23.5382	
			15 Days	4.16667	13.56568	.761	-23.5382	31.8715	
			30 Days	-12.50000	13.56568	.364	-40.2048	15.2048	
			45 Days	-16.66667	13.56568	.229	-44.3715	11.0382	
			2 Days	0 Day	.00000	13.56568	1.000	-27.7048	27.7048
			7 Days	-4.16667	13.56568	.761	-31.8715	23.5382	
			15 Days	4.16667	13.56568	.761	-23.5382	31.8715	
			30 Days	-12.50000	13.56568	.364	-40.2048	15.2048	
			45 Days	-16.66667	13.56568	.229	-44.3715	11.0382	
			7 Days	0 Day	4.16667	13.56568	.761	-23.5382	31.8715
			2 Days	4.16667	13.56568	.761	-23.5382	31.8715	
			15 Days	8.33333	13.56568	.544	-19.3715	36.0382	
			30 Days	-8.33333	13.56568	.544	-36.0382	19.3715	
			45 Days	-12.50000	13.56568	.364	-40.2048	15.2048	
			15 Days	0 Day	-4.16667	13.56568	.761	-31.8715	23.5382
			2 Days	-4.16667	13.56568	.761	-31.8715	23.5382	
			7 Days	-8.33333	13.56568	.544	-36.0382	19.3715	
			30 Days	45 Days	-16.66667	13.56568	.229	-44.3715	11.0382
			45 Days	0 Day	12.50000	13.56568	.364	-15.2048	40.2048
			2 Days	12.50000	13.56568	.364	-15.2048	40.2048	
			7 Days	8.33333	13.56568	.544	-19.3715	36.0382	
			15 Days	16.66667	13.56568	.229	-11.0382	44.3715	
			45 Days	-4.16667	13.56568	.761	-31.8715	23.5382	
			45 Days	0 Day	16.66667	13.56568	.229	-11.0382	44.3715
2 Days	16.66667	13.56568	.229	-11.0382	44.3715				
7 Days	12.50000	13.56568	.364	-15.2048	40.2048				
15 Days	20.83333	13.56568	.135	-6.8715	48.5382				
30 Days	4.16667	13.56568	.761	-23.5382	31.8715				
High Dose	LSD	0 Day	2 Days	.00000	8.67361	1.000	-17.7139	17.7139	
7 Days			.00000	8.67361	1.000	-17.7139	17.7139		
15 Days			8.33333	8.67361	.344	-9.3805	26.0472		
30 Days			-20.83333(*)	8.67361	.023	-38.5472	-3.1195		
45 Days			-33.33333(*)	8.67361	.001	-51.0472	-15.6195		
2 Days			0 Day	.00000	8.67361	1.000	-17.7139	17.7139	
7 Days			.00000	8.67361	1.000	-17.7139	17.7139		
15 Days			8.33333	8.67361	.344	-9.3805	26.0472		
30 Days			-20.83333(*)	8.67361	.023	-38.5472	-3.1195		
45 Days			-33.33333(*)	8.67361	.001	-51.0472	-15.6195		
7 Days			0 Day	.00000	8.67361	1.000	-17.7139	17.7139	
2 Days			.00000	8.67361	1.000	-17.7139	17.7139		
15 Days			8.33333	8.67361	.344	-9.3805	26.0472		
30 Days			-20.83333(*)	8.67361	.023	-38.5472	-3.1195		
45 Days			-33.33333(*)	8.67361	.001	-51.0472	-15.6195		
15 Days			0 Day	-8.33333	8.67361	.344	-26.0472	9.3805	
2 Days			-8.33333	8.67361	.344	-26.0472	9.3805		
7 Days			-8.33333	8.67361	.344	-26.0472	9.3805		
30 Days			-29.16667(*)	8.67361	.002	-46.8805	-11.4528		
45 Days			-41.66667(*)	8.67361	.000	-59.3805	-23.9528		
30 Days			0 Day	20.83333(*)	8.67361	.023	3.1195	38.5472	
2 Days			20.83333(*)	8.67361	.023	3.1195	38.5472		

		7 Days	20.83333(*)	8.67361	.023	3.1195	38.5472	
		15 Days	29.16667(*)	8.67361	.002	11.4528	46.8805	
		45 Days	-12.50000	8.67361	.160	-30.2139	5.2139	
	45 Days	0 Day	33.33333(*)	8.67361	.001	15.6195	51.0472	
		2 Days	33.33333(*)	8.67361	.001	15.6195	51.0472	
		7 Days	33.33333(*)	8.67361	.001	15.6195	51.0472	
		15 Days	41.66667(*)	8.67361	.000	23.9528	59.3805	
		30 Days	12.50000	8.67361	.160	-5.2139	30.2139	
Drug	LSD	0 Day	2 Days	.00000	11.28339	1.000	-23.0437	23.0437
			7 Days	20.83333	11.28339	.075	-2.2104	43.8771
			15 Days	20.83333	11.28339	.075	-2.2104	43.8771
			30 Days	33.33333(*)	11.28339	.006	10.2896	56.3771
			45 Days	8.33333	11.28339	.466	-14.7104	31.3771
		2 Days	0 Day	.00000	11.28339	1.000	-23.0437	23.0437
			7 Days	20.83333	11.28339	.075	-2.2104	43.8771
			15 Days	20.83333	11.28339	.075	-2.2104	43.8771
			30 Days	33.33333(*)	11.28339	.006	10.2896	56.3771
			45 Days	8.33333	11.28339	.466	-14.7104	31.3771
		7 Days	0 Day	-20.83333	11.28339	.075	-43.8771	2.2104
			2 Days	-20.83333	11.28339	.075	-43.8771	2.2104
			15 Days	.00000	11.28339	1.000	-23.0437	23.0437
			30 Days	12.50000	11.28339	.277	-10.5437	35.5437
			45 Days	-12.50000	11.28339	.277	-35.5437	10.5437
		15 Days	0 Day	-20.83333	11.28339	.075	-43.8771	2.2104
			2 Days	-20.83333	11.28339	.075	-43.8771	2.2104
			7 Days	.00000	11.28339	1.000	-23.0437	23.0437
			30 Days	12.50000	11.28339	.277	-10.5437	35.5437
			45 Days	-12.50000	11.28339	.277	-35.5437	10.5437
		30 Days	0 Day	-33.33333(*)	11.28339	.006	-56.3771	-10.2896
			2 Days	-33.33333(*)	11.28339	.006	-56.3771	-10.2896
			7 Days	-12.50000	11.28339	.277	-35.5437	10.5437
			15 Days	-12.50000	11.28339	.277	-35.5437	10.5437
			45 Days	-25.00000(*)	11.28339	.034	-48.0437	-1.9563
		45 Days	0 Day	-8.33333	11.28339	.466	-31.3771	14.7104
			2 Days	-8.33333	11.28339	.466	-31.3771	14.7104
			7 Days	12.50000	11.28339	.277	-10.5437	35.5437
			15 Days	12.50000	11.28339	.277	-10.5437	35.5437
			30 Days	25.00000(*)	11.28339	.034	1.9563	48.0437
Untreated	LSD	0 Day	2 Days	.00000	13.22000	1.000	-26.9989	26.9989
			7 Days	37.50000(*)	13.22000	.008	10.5011	64.4989
			15 Days	95.83333(*)	13.22000	.000	68.8345	122.8322
			30 Days	112.50000(*)	13.22000	.000	85.5011	139.4989
			45 Days	125.00000(*)	13.22000	.000	98.0011	151.9989
		2 Days	0 Day	.00000	13.22000	1.000	-26.9989	26.9989
			7 Days	37.50000(*)	13.22000	.008	10.5011	64.4989
			15 Days	95.83333(*)	13.22000	.000	68.8345	122.8322
			30 Days	112.50000(*)	13.22000	.000	85.5011	139.4989
			45 Days	125.00000(*)	13.22000	.000	98.0011	151.9989
		7 Days	0 Day	-37.50000(*)	13.22000	.008	-64.4989	-10.5011
			2 Days	-37.50000(*)	13.22000	.008	-64.4989	-10.5011
			15 Days	58.33333(*)	13.22000	.000	31.3345	85.3322
			30 Days	75.00000(*)	13.22000	.000	48.0011	101.9989
			45 Days	87.50000(*)	13.22000	.000	60.5011	114.4989
		15 Days	0 Day	-95.83333(*)	13.22000	.000	-122.8322	-68.8345

	2 Days	-95.833333(*)	13.22000	.000	-122.8322	-68.8345
	7 Days	-58.333333(*)	13.22000	.000	-85.3322	-31.3345
	30 Days	16.66667	13.22000	.217	-10.3322	43.6655
	45 Days	29.16667(*)	13.22000	.035	2.1678	56.1655
30 Days	0 Day	-112.50000(*)	13.22000	.000	-139.4989	-85.5011
	2 Days	-112.50000(*)	13.22000	.000	-139.4989	-85.5011
	7 Days	-75.00000(*)	13.22000	.000	-101.9989	-48.0011
	15 Days	-16.66667	13.22000	.217	-43.6655	10.3322
	45 Days	12.50000	13.22000	.352	-14.4989	39.4989
45 Days	0 Day	-125.00000(*)	13.22000	.000	-151.9989	-98.0011
	2 Days	-125.00000(*)	13.22000	.000	-151.9989	-98.0011
	7 Days	-87.50000(*)	13.22000	.000	-114.4989	-60.5011
	15 Days	-29.16667(*)	13.22000	.035	-56.1655	-2.1678
	30 Days	-12.50000	13.22000	.352	-39.4989	14.4989

* The mean difference is significant at the .05 level.

Table 40: Duncan multiple range tests: Fasting body weights within normal group

	Time	N	Subset for alpha = .05		
			1	2	3
Duncan(a)	0 Day	6	258.3333		
	2 Days	6	258.3333		
	7 Days	6	279.1667	279.1667	
	15 Days	6		287.5000	
	30 Days	6			314.1667
	45 Days	6			326.6667
	Sig.		.057	.412	.222

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 41: Duncan multiple range tests: Fasting body weights within low dose treated group

	Time	N	Subset for alpha = .05
			1
Duncan(a)	15 Days	6	233.3333
	0 Day	6	237.5000
	2 Days	6	237.5000
	7 Days	6	241.6667
	30 Days	6	250.0000
	45 Days	6	254.1667
	Sig.		.187

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 42: Duncan multiple range tests: Fasting body weights within high dose treated group

Time	N	Subset for alpha = .05	
		1	2
Duncan(a) 15 Days	6	245.8333	
0 Day	6	254.1667	
2 Days	6	254.1667	
7 Days	6	254.1667	
30 Days	6		275.0000
45 Days	6		287.5000
Sig.		.389	.160

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 43: Duncan multiple range tests: Fasting body weights within drug treated group

Time	N	Subset for alpha = .05	
		1	2
Duncan(a) 30 Days	6	216.6667	
7 Days	6	229.1667	229.1667
15 Days	6	229.1667	229.1667
45 Days	6		241.6667
0 Day	6		250.0000
2 Days	6		250.0000
Sig.		.305	.108

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 44: Duncan multiple range tests: Fasting body weights within untreated group

Time	N	Subset for alpha = .05			
		1	2	3	4
Duncan(a) 45 Days	6	195.8333			
30 Days	6	208.3333	208.3333		
15 Days	6		225.0000		
7 Days	6			283.3333	
0 Day	6				320.8333
2 Days	6				320.8333
Sig.		.352	.217	1.000	1.000

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 45: Descriptives: Fasting insulin level at day 45

Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
Normal	6	1.6617	0.21628	0.08830	1.4347	1.8886	1.41	1.98
Low Dose	6	1.5967	0.06713	0.02741	1.5262	1.6671	1.49	1.66
High Dose	6	1.6600	0.15773	0.06439	1.4945	1.8255	1.51	1.95

Drug	6	1.0350	0.10035	0.04097	0.9297	1.1403	0.86	1.15
Untreated	6	0.5333	0.13261	0.05414	0.3942	0.6725	0.39	0.72
Total	30	1.2973	0.47552	0.08682	1.1198	1.4749	0.39	1.98

Table 46: ANOVA: Fasting insulin level at day 45

Group	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	6.038	4	1.510	72.701	.000
Within Groups	.519	25	.021		
Total	6.557	29			

Table 47: Multiple comparisons: Fasting insulin level at day 45

(I) Group	(J) Group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval		
					Lower Bound	Upper Bound	
LSD	Normal	Low Dose	0.06500	0.08319	0.442	-0.1063	0.2363
		High Dose	0.00167	0.08319	0.984	-0.1697	0.1730
	Drug	Untreated	0.62667(*)	0.08319	0.000	0.4553	0.7980
		Untreated	1.12833(*)	0.08319	0.000	0.9570	1.2997
Low Dose	Normal	High Dose	-0.06500	0.08319	0.442	-0.2363	0.1063
		High Dose	-0.06333	0.08319	0.454	-0.2347	0.1080
	Drug	Untreated	0.56167(*)	0.08319	0.000	0.3903	0.7330
		Untreated	1.06333(*)	0.08319	0.000	0.8920	1.2347
High Dose	Normal	Low Dose	-0.00167	0.08319	0.984	-0.1730	0.1697
		Low Dose	0.06333	0.08319	0.454	-0.1080	0.2347
	Drug	Untreated	0.62500(*)	0.08319	0.000	0.4537	0.7963
		Untreated	1.12667(*)	0.08319	0.000	0.9553	1.2980
Drug	Normal	High Dose	-0.62667(*)	0.08319	0.000	-0.7980	-0.4553
		High Dose	-0.56167(*)	0.08319	0.000	-0.7330	-0.3903
	Untreated	High Dose	-0.62500(*)	0.08319	0.000	-0.7963	-0.4537
		Untreated	0.50167(*)	0.08319	0.000	0.3303	0.6730
Untreated	Normal	Low Dose	-1.12833(*)	0.08319	0.000	-1.2997	-0.9570
		Low Dose	-1.06333(*)	0.08319	0.000	-1.2347	-0.8920
	High Dose	Drug	-1.12667(*)	0.08319	0.000	-1.2980	-0.9553
		Drug	-0.50167(*)	0.08319	0.000	-0.6730	-0.3303

* The mean difference is significant at the .05 level.

Table 48: Duncan multiple range tests: Fasting insulin level at day 45

Group	N	Subset for alpha = .05		
		1	2	3
Duncan(a)	Untreated	6	0.5333	
	Drug	6		1.0350
	Low Dose	6		1.5967
	High Dose	6		1.6600
	Normal	6		1.6617
	Sig.		1.000	1.000
				0.469

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 6.000.

Table 49: Descriptives: Fasting catalase level at day 45

Group	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
Normal	3	101.8767	4.07413	2.35220	91.7560	111.9974	97.43	105.43
Low Dose	3	100.7667	2.33500	1.34811	94.9662	106.5671	98.43	103.10
High Dose	3	103.6567	2.69251	1.55452	96.9681	110.3452	100.77	106.10
Drug	3	96.1000	2.84937	1.64508	89.0218	103.1782	93.43	99.10
Untreated	3	53.0967	1.52753	.88192	49.3021	56.8912	51.43	54.43
Total	15	91.0993	19.98038	5.15891	80.0346	102.1641	51.43	106.10

Table 50: ANOVA: Fasting catalase level at day 45

Group	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	5509.513	4	1377.378	173.244	.000
Within Groups	79.505	10	7.951		
Total	5589.018	14			

Table 51: Multiple comparisons: Fasting catalase level at day 45

(I)Group	(J)Group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval		
					Lower Bound	Upper Bound	
LSD	Normal	Low Dose	1.11000	2.30225	.640	-4.0197	6.2397
		High Dose	-1.78000	2.30225	.457	-6.9097	3.3497
	Drug	5.77667(*)	2.30225	.031	.6469	10.9064	
	Untreated	48.78000(*)	2.30225	.000	43.6503	53.9097	
Low Dose	Normal	Low Dose	-1.11000	2.30225	.640	-6.2397	4.0197
		High Dose	-2.89000	2.30225	.238	-8.0197	2.2397
	Drug	4.66667	2.30225	.070	-.4631	9.7964	
	Untreated	47.67000(*)	2.30225	.000	42.5403	52.7997	
High Dose	Normal	Low Dose	1.78000	2.30225	.457	-3.3497	6.9097
		High Dose	2.89000	2.30225	.238	-2.2397	8.0197
	Drug	7.55667(*)	2.30225	.008	2.4269	12.6864	
	Untreated	50.56000(*)	2.30225	.000	45.4303	55.6897	
Drug	Normal	Low Dose	-5.77667(*)	2.30225	.031	-10.9064	-.6469
		High Dose	-4.66667	2.30225	.070	-9.7964	.4631
	High Dose	-7.55667(*)	2.30225	.008	-12.6864	-2.4269	
	Untreated	43.00333(*)	2.30225	.000	37.8736	48.1331	
Untreated	Normal	Low Dose	-48.78000(*)	2.30225	.000	-53.9097	-43.6503
		High Dose	-47.67000(*)	2.30225	.000	-52.7997	-42.5403
	High Dose	-50.56000(*)	2.30225	.000	-55.6897	-45.4303	
	Drug	-43.00333(*)	2.30225	.000	-48.1331	-37.8736	

* The mean difference is significant at the .05 level.

Table 52: Duncan multiple range tests: Fasting catalase level at day 45

Group	N	Subset for alpha = .05		
		1	2	3
Duncan(a)	Untreated	3	53.0967	
	Drug	3		96.1000
	Low Dose	3		100.7667

Normal	3			101.8767
High Dose	3			103.6567
Sig.		1.000	.070	.258

Means for groups in homogeneous subsets are displayed.

a Uses Harmonic Mean Sample Size = 3.000.